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ABSTRACT
Congenital heart defects and adult calcific aortic valve disease are two of
the leading causes of morbidity and mortality worldwide. To date, there is no
medical cure and surgical intervention is the main option of treatment. The cardiac
outflow tract is the major site for these abnormalities, which are triggered by
genetic and/or environmental factors that alter development and/or homeostasis.
Recently, significant roles of TGFβ signaling in development of cardiovascular
disorders have become more evident in humans, however, the specific
requirement of individual TGFβ ligands on the pathogenesis of OFT malformations
and diseases remains elusive. In the present work, three studies are conducted to
understand the role of Tgfb1 in calcific aortic valve diseases, the cell-type specific
role of Tgfb2 in OFT malformations, and the role of Tgfb3 in OFT malformations
and myocardial development.
Augmented TGFβ1 signaling is reported in human patients with calcific
aortic valve disease, the major cause of valve replacement surgery in the United
States. However, the role of TGFβ1 in CAVD pathogenesis has not been
investigated in vivo. In the first study, we generated for the first time Tgfb1Tg; Pericre

Tg

mouse model with overexpression of bioactive TGFβ1 in valve interstitial

cells (VICs) and we conduct a longitudinal follow-up study during embryonic and
adult lives (E13.5-1 year). We were able to recapitulate human-like CAVD with

vi

Tgfb1 hyperactivation signature spontaneously and without using dietary or
pharmacological triggers. We found significant gender differences in CAVD
progression with male mice tending to have a more severe form of the disease and
development of bicuspid aortic valves, the most prevalent cardiovascular
malformation in humans. Finally, we were able to attenuate disease progression,
but not development, using pharmacological and genetic approaches. Collectively,
our study implies that Tgfb1 signaling causes the onset and progression of CAVD
in mice and interfering with its pathway as new targeted therapy is warranted.
Cardiac outflow tract malformations are the major and most critical types of
congenital heart defects. Tgfb2 and Tgfb3 mutations have been reported in human
patients with Loeys-Dietz syndrome and/or Arrhythmogenic Right Ventricular
Dysplasia, however, their roles in the pathogeneses of these diseases remain
unknown. In the second study, we used the novel Tgfb2 flox/flox mice and we deleted
Tgfb2 from the endocardial, myocardial, and neural crest cells using tissue specific
Cre mice. We found overlapping and distinct roles of Tgfb2 in OFT morphogenesis
and we identified a novel finding that endocardial-produced Tgfb2 regulates OFT
septation in a paracrine manner. In the third study, we generated and analyzed a
large sample of Tgfb3 systemic knockouts embryos. We found that a significant
number of mice develop cardiac valve remodeling defects and abnormal right
ventricular myocardium but with incomplete penetrance. Overall, this work
provides novel mechanisms which enhance our knowledge of the roles of TGFβ
1-3 ligands in OFT development and disease that could help in identifying targeted
therapy or diagnostic biomarkers in the future.
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CHAPTER 1
OVERVIEW OF THE ROLE OF TRANSFORMING GROWTH FACTOR BETA
(TGFΒ) LIGANDS IN CARDIAC OUTFLOW TRACT DEVELOPMENT AND
DISEASE
The cardiac outflow tract (OFT) is a short canal connecting the primitive
ventricles to the pulmonary and aortic vasculatures during heart development(Lin,
Lin, Chen, Zhou, & Chang, 2012; Neeb, Lajiness, Bolanis, & Conway, 2013).
Cardiac OFT is one of the most common site of congenital heart defects (Neeb et
al., 2013). Lineage tracing studies have shown that multiple progenitor cells are
required for OFT formation (Meilhac, Lescroart, Blanpain, & Buckingham, 2014),
however, the cross talk among these cells and the downstream transcriptional
regulations are not fully understood. TGFβ ligands are multifunctional cytokines
produced by cardiac and non-cardiac cell lineages in spatiotemporal patterns
during heart development (Molin et al., 2003). Growing evidence from clinical
studies have revealed the potential role of TGFβ mutations and/or dysregulation in
cardiac OFT malformations (Bertoli-Avella et al., 2015; Lindsay et al., 2012).
Global Knockouts of Tgfb signaling in mice have also shown diverse
cardiovascular phenotypes (Doetschman, Barnett, et al., 2012), however, the celltype specific requirements of Tgfb ligands in cardiac OFT development and
homeostasis remain not fully understood. This chapter serves as a brief overview
of heart anatomy and development, TGFβ signaling, the synthesis of TGFβ
ligands, TGFβ receptor activation and signal transduction, and the implications of
1

TGFβ signaling in human cardiovascular diseases and malformations.
1.1 Structure, function, and development of the mammalian heart:
The heart is a tri-layered muscular organ located in the central part of the
thoracic cavity (middle mediastinum) and is composed of inner liningendocardium, muscular wall- myocardium, and outer layer- epicardium (Anderson,
Razavi, & Taylor, 2004; Lin et al., 2012). The heart receives highly oxygenated
blood from the lung and pumps it to the rest of the body, similarly, it receives low
oxygenated blood from the body and pumps it back to the lung for re-oxygenation
(Weinhaus, 2015). The heart’s function depends mainly on its intricate structure of
four chambers ( Figure 1.1), the right and left atria and ventricles, and the four
valves located at the outlet of each chamber that ensure unidirectional blood flow
during cardiac systole (contraction) and diastole (relaxation) (Anderson et al.,
2004; Weinhaus, 2015). On the left heart side, oxygen rich blood arrives from the
lung to the left atrium via four pulmonary veins (Anderson et al., 2004; Weinhaus,
2015). The mitral valve regulates blood flow from the left atrium to the left ventricle,
while the aortic valve regulates blood flow from the left ventricle to the aorta
(systemic circulation) (Anderson et al., 2004; Weinhaus, 2015). On the right heart
side, blood deficit in oxygen arrives at the right atrium via the superior and inferior
vena cava (Weinhaus, 2015). The tricuspid valve regulates blood flow from the
right atrium to the right ventricle, while the pulmonary valve regulated blood flow
from the right ventricle to the pulmonary artery (pulmonary circulation) (Anderson
et al., 2004; Weinhaus, 2015).

2

Heart development is a complex process characterized by commitment
and differentiation of the cells of the cardiogenic mesoderm, formation and looping
of the heart tube, alignment, and then septation and remolding of the cardiac
outflow tract and chambers (Figure 1.1).The heart is the first organ to function in
human and in mice (Krishnan et al., 2014). With the exception of mice having a
prominent atrium, bilateral superior vena cava, and merged pulmonary veins
opening to the left atrium, most structures and sequalae of developmental events
are similar between these two mammalian species (Krishnan et al., 2014).
Heart formation starts at the time of gastrulation in which the embryonic
blastula develops into three germ layers: the ectoderm, mesoderm, and endoderm
(around day 7 in mice and week 3 in humans) (Lawson, Meneses, & Pedersen,
1991; A. Moorman, Webb, Brown, Lamers, & Anderson, 2003). Initially, a group of
mesodermal cells, located anterior to the primitive streak, migrate toward the
visceral mesoderm and form what is called the cardiac crescent (Abu-Issa & Kirby,
2007). Cardiac crescent first heart field (FHF) cells proliferate and fuse to form a
tubular structure called the primary heart tube (Abu-Issa & Kirby, 2007). Further
elongation of the heart tube occurs when another group of mesodermal cells, also
known as the second heart field cells, are gradually added at both the arterial and
venous poles (Lin et al., 2012; A. Moorman et al., 2003). As the heart grows, it
undergoes further looping and patriation into distinct segments that include the
arterial pole, the outflow tract, the primitive right ventricle, the primitive left
ventricle, the common atrium, and the venous pole (Lin et al., 2012).

3

The cardiac outflow tract (OFT) is a an embryonic canal-like structure
connecting the developing pulmonary and aortic trunks to the primitive cardiac
chambers (Neeb et al., 2013). In the linear heart tube, the OFT is composed of two
layers, the outer- myocardium and inner- endocardium (Neeb et al., 2013). Initially,
the OFT connects the arterial pole of developing heart to the primitive right
ventricle (Neeb et al., 2013). During heart looping, localized acellular expansion,
known as the endocardial cushions, appear at the proximal and distal portions of
the OFT (Lin et al., 2012; Neeb et al., 2013). In the proximal outflow tract, groups
of endocardial cells transform into mesenchymal-like cells, via endothelialmesenchymal transformation (EMT), and secrete layer-specific extracellular matrix
(collagen, proteoglycan , and elastin) (Chopra, Al-Sammarraie, Lai, & Azhar, 2017;
Lin et al., 2012; Person, Klewer, & Runyan, 2005). Proximal endocardial cushions
(conal cushions) contribute to the formation of the pulmonary valve, aortic valve,
and the septa of left and right ventricular outlets (Anderson, Webb, Brown, Lamers,
& Moorman, 2003b; Lin et al., 2012; Srivastava, 2006). In the distal outflow tract,
cardiac neural crest cells (neuroectoderm cells) migrate and populate the distal
cushion (truncal cushion) and contribute to pulmonary and aortic trunk septation
(Anderson et al., 2003b; Lin et al., 2012; Srivastava, 2006). The cardiac outflow
tract undergoes further remodeling and develops into the arterial roots,
intrapericardial pulmonary and aortic trunks, and sub-valvar ventricular outflow
tracts in the definitive heart (Anderson, Mori, Spicer, Brown, & Mohun, 2016).
Likewise, the cardiac atrioventricular cushions develop as four acellular masses at
the canal connecting the primitive atria and ventricle (AV canal) (Dyer LA, 2014).
4

As the heart grows, AV cushions are populated by EMT-derived cushion
mesenchyme cells to form the superior and inferior cushions, while the left and
right lateral cushions are largely populated by epicardial derived cells (Dyer LA,
2014; Wessels et al., 2012). The AV cushion mesenchyme cells contribute to
septations of heart chambers and lead to the formation of mitral and tricuspid
valves (Dyer LA, 2014; Wessels et al., 2012).
Similarly, the formation and septation of the cardiac chambers results from
the contribution of multiple cell lineages. The myocardium of the atrium, ventricles
and outflow tract develops from the two heart fields (A. Moorman et al., 2003). The
first heart field contributes to the left ventricle and part of the right ventricle and
atrium(Lin et al., 2012). On other hand, most of the right ventricle and the outflow
tract, and part of left ventricle and atria are formed by contribution of the second
heart field cells (Dyer & Kirby, 2009; Lin et al., 2012; A. Moorman et al., 2003).
Chamber septation develops via a complex interaction between the myocardial
and cushion mesenchymal cells. Atrial septum develops from three components:
the outgrowth of myocardial septa from the roof of primitive atrium, the EMTderived mesenchymal cup which covers the leading edge of muscular septa and
eventually fuse to the superior AV cushion, and the SHF-derived dorsal
mesenchymal protrusion (DMP) (Anderson, Brown, & Webb, 2002; Burns, Yang,
Hiriart, & Wessels, 2016). Similarly, the interventricular septum develops as
muscular and perimembranous components. As the heart tube undergo looping,
muscular septa grow from the apex of the primary heart tube (trabecular fold) to
separate the left and right ventricles. The perimembranous septum is formed via
5

fusion of the superior and inferior AV cushions to the crescent-like leading edge of
the enlarged muscular septa (Anderson, Webb, Brown, Lamers, & Moorman,
2003a; Lin et al., 2012).
Regulation of heart tube formation, septation, alignment and remodeling are
under tight control of signaling molecules that regulate cell fate specifications,
migration and differentiation during heart development. TGFβ ligands are amongst
the most crucial cytokines which regulate heart development and remodeling,
while disruptions of TGFβ ligands have been linked to human congenital heart
defects (e.g Loeys-Dietz syndrome) and adult cardiovascular diseases (e.g calcific
aortic valve stenosis). However, the cell-type specific role and the downstream
targets of TGFβ ligands in the pathogenesis of OFT malformations and diseases
remain unknown.
1.2 Overview of TGFβ signaling:
The TGFβ superfamily is a group of structurally related growth and
differentiation proteins encoded by more than 33 different genes in mammalian
cells (Morikawa, Derynck, & Miyazono, 2016). The TGFβ superfamily includes the
bone morphogenetic proteins (BMPs), activins/ inhibin, MIF (Müllerian inhibitory
factor), growth and differentiation factors (GDFs), and TGFβs (Gordon & Blobe,
2008; Weiss & Attisano, 2013). TGFβs (1-3) ligands are multifunctional proteins
secreted by various cell types to form inactive mature peptides which are
sequestered in the extracellular matrix until activated (Sengle, Ono, Sasaki, &
Sakai, 2011; M. Shi et al., 2011). Although they are products of three different
genes, TGFβ1-3 ligands share similarities in their dimeric protein structures (Hinck,
6

2012; Morikawa et al., 2016). Upon activation, ligands bind to the cell surface
TGFβ receptors and activate the downstream SMAD dependent and/or
independent pathways (Y. Shi & Massagué, 2003; Weiss & Attisano, 2013). TGFβ
ligands are expressed by most cell types during embryonic and adult lives to
regulate organ development and maintain tissue homeostasis (Wu & Hill, 2009).
At the cellular and molecular levels, TGFβ ligands regulate the expression of genes
involved in cell proliferation, apoptosis, cell matrix remolding, differentiation,
migration, epithelial mesenchymal transition, and cell cycle regulation in cell-type
specific and context-dependent manner (Gordon & Blobe, 2008; Morikawa et al.,
2016).
1.3 TGFβ ligand structure and synthesis:
TGFβ ligands are dimeric proteins (Figure 1.2) transcribed from three
different genes located on three different chromosomes in the human genome:
TGFβ 1 gene located on the long arm of chromosome 19 (Chromosome 19q13.2)
(HGNC:HGNC:11766), TGFβ 2 gene located on long arm of chromosome 1
(Chromosome 1q41) (HGNC:HGNC:11768), and TGFβ 3 gene located on long
arm of chromosome 14 (chromosome 14q24.3) (HGNC:HGNC:11769). TGFβ
dimers are two identical polypeptides chains composed of alpha helices and beta
strands which are held together by inter-chain disulfide bridges (Hinck, 2012).
TGFβ ligands are translated into the endoplasmic reticulum as inactive proteins
called the small latency complex (SLC) which consists of the TGF-β mature
peptide at the C-terminus and the latency associated peptide (LAP) at the N
terminus (Robertson & Rifkin, 2016).
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The function of LAP is to cover the binding site of the mature peptide and
prevent its association with the TGFβ receptor upon secretion (Robertson & Rifkin,
2016). Once in the endoplasmic reticulum, SLC is further folded, dimerized,
cleaved and linked to a bigger protein called the latent TGFβ-binding proteins
(LTBPs) via disulfide bonds to form the large latent complex (LLC) (Constam,
2014; Robertson & Rifkin, 2016). The function of LLC is to direct TGFβ ligands to
bind to the extracellular proteins, mainly fibrillin and fibronectin, until the mature
peptide is released (Constam, 2014; Robertson & Rifkin, 2016).
Activation and release of mature TGFβ dimers are regulated by the physical
and chemical environment of the ECM (e.g pH), enzymatic cleavage by proteases,
and/or mechanical traction forces generated by the cell surface integrins
(Constam, 2014; Robertson & Rifkin, 2016). Once released, the soluble protein
binds and assembles TGFβ receptor I and II complex on the same cell (autocrine)
or other cells (paracrine) and induce SMAD (canonical pathway) and/or non-SMAD
activation (none-canonical pathway) (Derynck & Zhang, 2003; Y. E. Zhang, 2009).
1.4 TGFβ Receptor activation and the downstream SMAD and Non-SMAD
pathways:
TGFβ receptors are dual speciﬁcity kinases belong to the tyrosine kinaselike (TKL) family (Heldin & Moustakas, 2016; Lawler et al., 1997). Upon activation
by TGFβ ligands (Figure1.3), the receptors can phosphorylate tyrosine and/ or
serine-threonine residues (Heldin & Moustakas, 2016; Lawler et al., 1997). TGFβ
(1-3) ligands can bind and activate similar receptor complex, namely the type I and
type II receptors, with or without the aid of coreceptors (Derynck & Zhang, 2003;
Moustakas et al., 1993). TGFβ1 and 3 bind receptor II with high affinity, however,
8

TGFβ 2 requires the betaglycan (TGFβ receptor III) coreceptor to increase its
affinity for binding the TGFβ receptor II (Cheifetz et al., 1987; López-Casillas,
Wrana, & Massagué, 1993; Moustakas et al., 1993; Sankar, Mahooti-Brooks,
Centrella, McCarthy, & Madri, 1995). The TGFβ receptor consists of three
domains: the extracellular binding domain, the short transmembrane domain, and
the long cytoplasmic kinase domain (Hinck, 2012). Upon release, the TGFβ
dimeric ligands bind to the extra-cytoplasmic domain of TGFβ receptor II and
induce assembly of two TGFβ receptor II and two receptor I complex (heteromeric
receptor complex) (Hata & Chen, 2016; Massagué, 2012). TGFβ receptor II, via its
constitutively active intracellular kinase, phosphorylates and activates TGFβ
receptor I which in turn phosphorylate and activate SMAD proteins (Hata & Chen,
2016; Massagué, 2012). SMAD proteins are signal transducer for TGFβ ligands
and they include: the receptor activated SMAD2 and 3 (R-SMADS 2/ 3), coreceptor SMAD4 (CO-SMAD4) a partner for SMAD2/3, and the inhibitory SMAD 7
(I-SMAD7) which interfere and inhibit further SMAD-SMAD or SMAD-receptor
interactions (Macias, Martin-Malpartida, & Massagué, 2015). The receptor
activated SMAD2/3 has two terminal domains and a middle linker region
(Moustakas, Souchelnytskyi, & Heldin, 2001). The amino-terminal domain (MH1)
contains DNA binding sites, while the carboxy- terminal domain (MH2) has
interaction sites for receptor, SMAD4 protein, anchor protein, chromatin modifiers,
and lineage-specific cofactors (J. Kim, Johnson, Chen, Carroll, & Laughon, 1997;
Macias et al., 2015; Massagué, 2012). The linker segment of R-SMAD 2/3 contains
phosphorylation site for cyclin-dependent kinases CDK8 and CDK9, which
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promote interaction of R-SMAD with co-activators (Alarcón et al., 2009; Macias et
al., 2015). This site acts also as a phosphorylation site for cell cycle kinases
(CDK4) and mitogen activated kinases (MAP kinases) pathways (Macias et al.,
2015; Sapkota et al., 2006). The linker region can switch to a negative regulator
site which binds to E3 ubiquitin ligases (E3 ligase) that marks R-SMAD for
proteasome degradation or it can be dephosphorylated by SCP1-3 phosphatases
to reverse SMAD binding (Macias et al., 2015; Sapkota et al., 2006; Wrighton et
al., 2006). Once activated, TGFβ receptor I phosphorylate SMAD2/3 at the
carboxy-terminus which then recruits and binds to SMAD4. SMAD2/3-SMAD4
complexes is translocated to the nucleus where SMAD3 and SMAD 4 can bind to
the SMAD binding element (SBE) in the DNA, also known as CAGA box
(Morikawa, Koinuma, Miyazono, & Heldin, 2013). On the other hand, SMAD2 bind
indirectly to the DNA due to presence of hindering sequences in exon 3 of SMAD
2 which prevent direct interaction (Yagi et al., 1999) SMAD2/3 interact with
coactivator/ corepressor to initiate or repress the expression of TGFβ target genes
(Simonsson, Kanduri, Grönroos, Heldin, & Ericsson, 2006). In addition to SMAD
activation, TGFβ ligands can activate non-SMAD pathways including the mitogenactivated protein kinases (ERK, JNK, and p38), the Rho-like GTPases (RhoA, Rac
and Cdc42), and phosphatidylinositol-3-kinase-AKT pathways which regulate
various cellular process during heart development and diseases (Y. E. Zhang,
2009). The non-SMAD pathways are activated by TGFβ receptors and can either
interact directly with SMAD proteins and modulate their actions or act through nonSMAD parallel pathway (Moustakas & Heldin, 2005).
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Most of non-SMAD

pathways are involved in regulation of EMT during embryonic development and in
diseases such as fibrosis (e.g., ERK, P38, JNK, and PI3K-AKT) (Y. E. Zhang,
2009). Theses pathways are powerful regulators of cell motility, actin filament
organization, dissolution of the tight junctions between adjacent cells, dissociation
of epithelial cells, and mesenchymal transformation during the EMT process (Y. E.
Zhang, 2009). On other hand, TGFβ-mediated apoptosis occurs through the
TAK1/JNK, p38, or SMAD pathways while TGFβ-mediated proliferation and
protein translation is regulated via the PI3K/Akt pathway (Y. E. Zhang, 2009). Fine
tuning of TGFβ signaling is under tight control of multiple mechanisms at the level
of transcription, translation, posttranslational modification, sequestration in ECM,
and extracellular agonist or antagonists (Chang, 2016; Moustakas et al., 2001;
Robertson & Rifkin, 2016; Y. Shi & Massagué, 2003). Disruption of one or more of
these TGFβ regulatory mechanisms can lead to developmental abnormalities and/
or adult diseases.
1.5 Dysregulation of TGFβ signaling in human cardiovascular diseases:
Although expressed by most cell types during cardiac OFT development
(Azhar et al., 2003; Doetschman, Barnett, et al., 2012; Molin et al., 2003), the loss
of function mutations in TGFβ1 have not been reported to cause congenital heart
defects in humans. On the other hand, TGFβ1 overexpression has been
associated with a significant number of adult cardiovascular disorders, including
Marfan syndrome, Loeys-Dietz syndrome, calcific aortic valve disease, tricuspid
and bicuspid aortic stenosis, chronic rheumatic heart disease, myocardial
infraction and heart failure (Glazer et al., 2012; Jian, Narula, Li, Mohler, & Levy,
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2003; L. Kim et al., 2008; Lindsay et al., 2012; Nataatmadja, West, & West, 2006;
Rueda-Martínez et al., 2017; Villar et al., 2009).
Overall, TGFβ1 is an important regulator of aortic wall and valve
homeostasis. TGFβ1 overexpression and increased TGFβ signaling have been
reported in patients with Loeys-Dietz syndrome (LDS), a widespread connective
tissue disorder characterized by skeletal and cardiovascular abnormalities. These
cardiovascular issues include blood vessel tortuosity, congenital heart defects,
aortic dilation, aortic aneurysm and aortic dissection (Lindsay et al., 2012; Loeys
et al., 2005). Lindsay et al performed immunohistochemical analysis on aortic wall
tissues obtained from Loeys-Dietz patients, whose primary defect was TGFβ2 loss
of function mutations (LDS type IV) (Lindsay et al., 2012). The results showed
reduced TGFβ2 expression, however, there was marked increases in TGFβ1,
SMAD2, and SMAD3 signaling (Lindsay et al., 2012). Although not fully
understood, this study suggested that the reciprocal increase in TGFβ1 signaling
could be compensatory for the loss in TGFβ2. TGFβ1 overexpression is also
reported in patients with aortic dilation in both tricuspid and bicuspid aortic
stenosis. TGFβ1 was higher in patients with aortic stenosis and positively
correlated with aortic valvular gradient and left ventricular mass (Villar et al., 2009).
Similarly, TGFβ 1 was higher in blood of patients with tricuspid and bicuspid
aortopathies or dilated aorta compared to controls (Forte et al., 2017; RuedaMartínez et al., 2017). Increased TGFβ1 was also reported in patients with calcific
aortic valve stenosis who undergo valve replacement surgery (Jian et al., 2003).
Jian et al. reported increased TGFβ1 signaling in aortic valve tissues resected from
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calcified aortic valve disease (CAVD) patients compared to non- calcified cusps
obtained from control subjects at time of autopsy (Jian et al., 2003). Although this
study suggests a correlation between TGFβ1 overexpression and CAVD, it
remains unknown whether TGFβ1 signaling contributes to diseases development
and/or progression. Likewise, TGFβ1 plays a significant role in regulation of tissue
fibrosis. For example, TGFβ1 overexpression is reported in patients with chronic
rheumatic heart disease (L. Kim et al., 2008). Kim et al. reported a positive
correlation between TGFβ1 expression and increased myofibroblasts proliferation,
inflammatory cell infiltration, calcification and fibrosis in mitral valves obtained from
patients with chronic rheumatic diseases (L. Kim et al., 2008). Similarly, high
TGFβ1 plasma levels were directly linked to the high incidence of heart failure in
the elderly and an increase in TGFβ1 was detected in patient with left ventricular
dysfunction after myocardial infraction (Devaux et al., 2011; Glazer et al., 2012).
On other hand, the expression of the three TGFβ ligands are increased in
patients with Marfan syndrome (MFS), a systemic connective tissue disorder
caused by mutations in the fibrillin-1 (FBN1) extracellular matrix protein
(Nataatmadja et al., 2006). Nataatmadja et al. performed immunohistochemical
analysis on aortic wall tissue obtained from MFS patients with aneurysms and
compared those to normal aortas (Nataatmadja et al., 2006). The results showed
increased expression of all three ligands and the hyaluronan extracellular matrix
protein which may interfere with aortic wall tissue repair leading towards aortic
aneurysm formation (Nataatmadja et al., 2006).
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Although augmented TGFβ1 signaling is reported in many cardiovascular
disorders, it remains unclear whether TGFβ1 activation is a cause or a result of
these diseases. In contrast, mutations in TGFβ2 or TGFβ3 are reported to cause
certain cardiovascular diseases in human. For example, TGFβ2 loss of function
mutation has been found in patients with LDS type IV (Lindsay et al., 2012; Ritelli
et al., 2014). Lindsay et al. have identified number of TGFβ2 mutations in patients
with LDS including nonsense mutations, missense mutations, in-frame deletions,
and frameshift deletions (Lindsay et al., 2012). These patients develop multiple
cardiovascular disorders early in life including: bicuspid aortic valve disease,
arterial tortuosity, and aortic root aneurysms (Lindsay et al., 2012). Similarly, Ritlli
et al. have identified novel splice sites mutations in TGFβ2 with less severe and a
later onset of various cardiovascular diseases (Ritelli et al., 2014), TGFβ2 genetic
variants were also reported in patients with Kawasaki disease, acute systemic
vasculitis with dilation of aortic root and coronary artery aneurysms (Shimizu et al.,
2011). Similarly, TGFβ3 is an important regulator of muscle and blood vessel
formation, mutations in this gene have been reported in LDS patients with aortic
aneurysms (LDS type IV) and arrhythmogenic right ventricular cardiomyopathy, a
replacement of ventricular cardiomyocytes with fibrofatty tissue (Beffagna et al.,
2005; Bertoli-Avella et al., 2015; Rienhoff et al., 2013).
Although human studies have shown the potential role of TGFβ ligands
mutations and/or dysregulations in multiple cardiovascular disorders, there is no
direct cause- effect correlation that can be concluded from these studies. The
complexity of the signaling pathways, redundancy, and overlapping role of the
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three TGFβ ligands, and the limited number of studies using tissue-specific
knockout mice makes elucidating the role of individual TGFβ ligands in the
pathogenesis of cardiovascular malformations difficult to discern. Using cell-type
specific and systemic mouse knockout models, the aim of this dissertation is to
provide a comprehensive understanding of the roles of the three TGFβ ligands in
the development and progression of calcific aortic valve diseases (Chapter 2),
pathogenesis of outflow tract malformations (Chapter 3), and development of
congenital heart defects (Chapter 4).
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Figure 1.1 Schematic of mouse heart development. The cardiac crescent
consists of the first heart field (FHF) and second heart field (SHF) mesoderm
(E7.5). The heart tube is composed of a primitive ventricle with arterial and
venous poles (E8.5). The looped heart consists of the outflow tract (OFT) and
atrioventricular (AVC) canal, OFT and AVC cushions, and the developing
muscular septa (E9.5). The mature adult heart has four chambers- a left atrium
(LA), a right atrium (RA), a left ventricle (LV), a right ventricle (RV)- and four
sets of valves- a pulmonary valve (PV), an aortic valve (AoV), a tricuspid valve
(TV), and a mitral valve (MV). The superior vena cava (SVC) and inferior vena
cava (IVC) drain blood from the body while the pulmonary artery (PLA) and
aorta (Ao) pump blood to the lungs or the rest of the body, respectively.
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Figure 1.2 TGFβ ligand structure. The small latency complex (SLC) is
composed of TGFβ dimers held together via disulfide bonds and the latency
associated peptides (LAP). The large latency complex (LLC) composed of the
SLC and the latent TGFβ binding peptide (LTBP) bind to extracellular matrix
(ECM) proteins
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Figure 1.3 TGFβ canonical and non-canonical pathways. Canonical
pathway includes SMAD2/3 activation, while the non-canonical pathways
include mitogen-activated protein kinases (ERK, JNK, and p38), Rho-like
GTPases (RhoA, Rac and Cdc42), and phosphatidylinositol-3-kinase-AKT.
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CHAPTER 2
THE ROLE OF TRANSFORMING GROWTH FACTOR BETA 1
(TGFβ1) IN DEVELOPMENT AND PROGRESSION OF CALCIFIC
AORTIC VALVE DISEASE
2.1 INTRODUCTION
2.1.1 Calcific Aortic Valve Disease (CAVD)- clinical insight and significance:
Calcific aortic valve disease (CAVD) is the third most prevalent cardiac
disorder after coronary vascular diseases and hypertension (Lerman, Prasad, &
Alotti, 2015; Pibarot & Dumesnil, 2007). CAVD is characterized by fibrotic
thickening and calcification of the aortic valve leaflets and hinge region of the valve
leading to altered morphology, decreased lumen functionality, and a progressive
deterioration of heart function (Gomez Stallons MV, 2016; Lindman et al., 2016).
CAVD usually affects adults aged 65 and over, for whom 25% have valve
thickening (sclerosis) and 2-5% develop valve stenosis (Heistad, Shanahan, &
Demer, 2013; Lindman, Bonow, & Otto, 2013; Stewart et al., 1997). Younger
populations with bicuspid aortic valves (BAV) develop CAVD, and the majority
required valve replacement surgery (George Tokmaji & Mol, 2013; Robert B.
Hinton, 2013; Ward, 2000). CAVD is often asymptomatic and found incidentally
during other physical examinations, or it can be associated with significant aortic
valve stenosis (AS) causing a restriction of systemic blood flow, left ventricular
volume overload, and left ventricular hypertrophy (Lindman et al., 2016; Vahanian
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& Otto, 2010). To date there is no medical cure or prevention for CAVD, and
without surgical replacement, patients with severe aortic stenosis eventually
progress to left ventricular dysfunction, heart failure, and mortality (Lindman et al.,
2013; Rosenhek et al., 2004). Recent studies suggest that CAVD is not only an
age-related calcification of the aortic valve, but instead, it is well-regulated
biomineralization process controlled by inflammatory and/or non-inflammatory
mechanisms (Lerman et al., 2015; Rajamannan et al., 2011). Furthermore, CAVD
involves the production of inflammatory and profibrotic cytokines with activation
and differentiation of valve interstitial cells (VICs) into myofibroblast and
osteoblast-like cells, which contribute to the fibrocalcific degeneration and
remodeling of aortic valves (Freeman & Otto, 2005; Rajamannan et al., 2011).
Overexpression of TGFβ1 has been reported in patients with calcific aortic stenosis
(Jian et al., 2003), however, its role in disease onset and progression remains
largely unknown. Using a series of genetic mouse models, the aim of present study
is to confirm and extend a previously found in vivo role of TGFβ1 in the
pathogenesis of CAVD. These findings could provide a potential diagnostic
biomarker or therapeutic target to halt or slow CAVD progression.
2.1.2 Aortic valve anatomy, histology, and development:
The aortic valve is a semilunar valve composed of three thin cusps (leaflets)
located at the junction of the left ventricular outlet and the ascending aorta (Tilea
et al., 2013). Each leaflet has 4 parts (Figure 2.1): the hinge region (attachment of
the leaflet’s base to the anulus), the belly (the main or the thicker portion of the
leaflet), the coapting surface, and the lannula (serve as the site of joining of three
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leaflets to ensure proper valve closure) (Misfeld & Sievers, 2007). The aortic valve
is located within the aortic root which is composed of the annulus, fibroelastic wall,
three leaflets, three commissures (the area of attachment of two adjacent leaflets
to the aortic wall), three sinuses of Valsalva (widenings or bulges at the aortic side
of the anulus), and three sinotubular junctions (a ridge or a margin on superior
part of the sinus which enable to distinct the upper end of leaflets’ attachment)
(Misfeld & Sievers, 2007). The aortic valve is a unidirectional valve which opens
during left ventricular contraction (systole) to allow blood flow to the aorta, and
closes during left ventricular relaxation (diastole) to prevent the reverse blood flow
to the left ventricle (Fukuta & Little, 2008).
Histologically, the aortic valve leaflet is composed of a single outer layer of
endothelial cells and three structurally different internal layers (Figure 2.2): the
fibrosa, spongiosa, and ventricularis; each named based on their proximity to the
aorta or left ventricle, respectively (Aikawa & Libby, 2017; Lerman et al., 2015).
The endothelial cell layer is composed of a single layer of flat cells in contact with
blood and surrounds the entire sides of the aortic valve leaflets (Lerman et al.,
2015). Endothelial cells serve not only as a protective and antithrombotic barrier,
but also, they regulate valve remodeling and homeostasis (Aikawa & Libby, 2017;
Lerman et al., 2015). The fibroblast-like valve interstitial cells (VICs) are the major
cell type that present in all three internal layers, while the rest of the cells are mix
of myofibroblast, smooth muscle, and haemopoietic-derived stem cells (A. C. Liu,
Joag, & Gotlieb, 2007; Taylor, Batten, Brand, Thomas, & Yacoub, 2003; Visconti
et al., 2006). Although VICs populate all three layers, the internal layers differ in
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the extracellular matrix composition produced by VICs cells: the fibrosa that face
the aorta, is composed mainly of collagen type I and III, the spongiosa or middle
layer, is composed mainly of proteoglycans, and the ventricularis which face the
left ventricle, is composed mainly of elastin (Aikawa & Libby, 2017; Lerman et al.,
2015). Valve Interstitial Cells (VICs) are quiescent fibroblast-like cells which play
an important role in the secretion and maintenance of the extracellular matrix, and
therefor are essential to maintaining the integrity of valve’s cusps (J. H. Chen, Yip,
Sone, & Simmons, 2009; Rutkovskiy et al., 2017). Based on molecular and
environmental stimuli, VICs can be activated as myofibroblast or differentiate into
various cell types including: chondrocytes, osteoblasts, and adipocytes (J. H. Chen
et al., 2009; Rutkovskiy et al., 2017).
Embryologically, aortic valves are derived from the conal, truncal and
intercalated cushions of the cardiac outflow tract (Martin et al., 2015). The conal
and truncal cushions contribute mostly to the left and right coronary leaflets, while
the intercalated cushions contribute mainly to the non-coronary leaflets (Martin et
al., 2015; Mifflin, Dupuis, Alcala, Russell, & Kern, 2018). Valve interstitial cells are
heterogenous cell populations derived from diverse cell lineages during heart
development (Martin et al., 2015). The cell origins of the aortic valve leaflets
(Figure 2.3) are mostly from the endocardial cells that overlay the OFT cushions
that undergo epithelial mesenchymal transition (EMT) and contribute to all three
aortic valve leaflets (de Lange et al., 2004; Martin et al., 2015). Cardiac neural
crest cells (CNCs) are another major cell lineage for the aortic valve development,
particularly in the left and right leaflets, however, CNCs make less contribution to
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the non-coronary leaflets (Phillips et al., 2013). On other hand and for long time,
myocardial cells were thought to have no contribution to the aortic valve
mesenchymal cells and to communicate with the endocardium only via paracrine
signals that regulate endocardial cushion formation (Martin et al., 2015). However,
recent lineage tracing studies have revealed that the myocardial cell lineage is
present within the intercalated cushions that form the non-coronary leaflets (Mifflin
et al., 2018). This novel finding suggests a cellular contribution of myocardial cell
precursors to the development of aortic valves, however, their function has yet to
be discovered. Development of the aortic valves involve sequential events that
start with OFT endocardial cushion formation, an acellular jelly-like expansion
between the endocardial and myocardial layers of the early heart tube (Lin et al.,
2012). Cell lineages then undergo EMT (endocardial) or migrate and invade the
cushion (cardiac neural crest) and differentiate into the cushion mesenchyme cells
,which develop into VICs (de Lange et al., 2004; Lin et al., 2012; Martin et al.,
2015). Then, primitive valve leaflets undergo remodeling and elongation with
extracellular matrix production and stratification to form the mature leaflet (Chopra
et al., 2017; R. B. Hinton et al., 2006)
2.1.3 Risk factors, pathology, and consequences of CAVD:
CAVD is a progressive disease characterized by valve thickening, fibrosis,
and calcific nodule formation with or without stenosis (Lerman et al., 2015;
Lindman et al., 2016). Early lesions of CAVD include endothelial damage and
localized subendothelial thickening that spread to the fibrosa layer of the leaflet
(Freeman & Otto, 2005; Otto, Kuusisto, Reichenbach, Gown, & O'Brien, 1994).
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Histological analysis of the early lesion shows microcalcification, lipoproteins
deposition, and inflammatory cells infiltration, particularly T cells and macrophages
(Freeman & Otto, 2005; Olsson, Thyberg, & Nilsson, 1999). In addition, valve
interstitial cells (VICs) with fibroblast-like features can either die via apoptosis and
trigger calcium deposition (dystrophic calcification), or they differentiate into
osteoblast-like cells with the formation of calcium phosphate (bone-like) nodules
at the base of the cusp or the hinge region (Gomez Stallons MV, 2016; Lindman
et al., 2016; Merryman & Schoen, 2013). Calcification usually extends from the
base of the cusp to the tip with multiple nodules formation that cause leaflet
stiffness, similarly, abnormal extensive valve thickening can leads to valve
malfunction and aortic valve stenosis (Turri et al., 1990; Wirrig & Yutzey, 2013).
In late stage CAVD, histopathological analysis of calcified valves in humans show
a mixture of dystrophic calcification, endochondral bone formation, and lamellar
bone development (Freeman & Otto, 2005; Mohler et al., 2001).
Although the etiology of CAVD is not fully understood, recent studies have
identified several atherogenic and non-atherogenic risk factors that increased an
individual’s likelihood to develop CAVD and for the individual to progress towards
valvular stenosis. These factors include structural or molecular defects within the
aortic valve itself and/or factors related to patient’s genetic and demographic
details. Clinical studies have showed that hypertension, smoking, male gender,
diabetes mellites and hyperlipidemia are potent risk factors to develop both
atherosclerosis and CVAD (Sathyamurthy & Alex, 2015). However, CAVD can
develop in aged individuals without evidence of atherosclerosis (Boudoulas,
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Triposkiadis, & Boudoulas, 2018). Genetic polymorphism and mutations have
been linked to increased risk of calcific aortic stenosis, for example: the presence
of vitamin D receptor gene variant , apolipoprotein E4 gene variant, TGFβ1 and
estrogen receptor polymorphisms in post-menopausal women, and NOTCH1
autosomal dominant mutation which associated with development of bicuspid and
calcific aortic stenosis (O'Brien, 2006). Besides age, bicuspid aortic valve is
another potent risk factor associated with early onset calcific aortic stenosis in
young populations (Beppu et al., 1993). Bicuspid aortic valve is an anatomical
defect in which the aortic valve has two leaflets (true BAV) or fusion of adjacent
cusps in tri-leaflets valve (pseudo BAV)

(Nanea, 2018). Initially BAV is

asymptomatic but with time it can cause impairment of the valve function and the
onset of CAVD in the 4th or 5th decades of life (Beppu et al., 1993). BAV usually
involves fusion of the left and right coronary, or the non-coronary leaflets with either
the right or left coronary leaflet (Koenraadt et al., 2016) .
BAV is the most prevalent congenital heart defect affecting 0.5-2% of the
population and males more than females (Basso et al., 2004; Roberts, 1970; Ward,
2000). BAV (Figure 2.4) is characterized by the presence of leaflets of different
sizes, a central ridge or raphe, and a smooth leaflet margin (Ward, 2000). Similarly,
degenerative diseases of the aortic valve, or post-rheumatic or post-inflammatory
disorders, can lead to fusion of the tricuspid valve margins and the development
of acquired BAV (Waller, Carter, Williams, Wang, & Edwards, 1973; Ward, 2000).
CAVD has a long latent asymptomatic phase, however, once calcific aortic
stenosis develops it can lead to numerous cardiovascular complications (Lindman
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et al., 2013; Lindman et al., 2016). CAVD can cause severe narrowing of the left
ventricle outflow with increased blood flow velocity, as a result, left ventricular
myocytes may undergo hypertrophy with activation of myofibroblast and collagen
deposition, or what is called “reactive interstitial fibrosis”, to overcome the volume
overload and maintain blood flow across the stenotic valve (Lindman et al., 2016;
Lorell & Carabello, 2000; Mewton, Liu, Croisille, Bluemke, & Lima, 2011). Severe
or prolonged stenosis can lead to severe diastolic dysfunction with an increase in
left ventricle filling, left atrium dilation, secondary pulmonary hypertension, and a
reduction in coronary blood flow (Lindman et al., 2013; Lindman et al., 2016). If left
untreated, calcific aortic stenosis can leads to heart failure and/or death within few
years after the onset of the disease (Lindman et al., 2016).
2.1.4 Clinical presentation, diagnosis, treatment, and prognosis of CAVD:
Calcific aortic valve disease takes years to develop and many patients
remain asymptomatic until the valve becomes so severely calcified that a stenosis
occurs or the leaflets become dysfunctional (Czarny & Resar, 2014; IzquierdoGómez et al., 2017; Vahanian & Otto, 2010). Aortic stenosis signs and symptoms
include: an impairment of left ventricular function, a reduction in cardiac output
such as exercise intolerance, syncope, exertional angina, and heart failure (Czarny
& Resar, 2014; Izquierdo-Gómez et al., 2017; Vahanian & Otto, 2010). The
prognosis of untreated calcific aortic valve stenosis worsens drastically with age,
and a large longitudinal study was performed on patients aged 63 or more with
asymptomatic calcific aortic stenosis to correlate echocardiograph results with the
endpoint outcomes (death or valve replacement surgery) (Otto et al., 1997). The
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results indicated that event free survival progressively declined from approximately
93±5% after one year to 26±10% after five years, and the main predictors were the
aortic valve jet velocity, mean gradient, and the functional valve area detected by
the echocardiogram (Otto et al., 1997). This study concluded that the prognosis of
calcific aortic stenosis can be predicted from early echocardiographic results in
clinically asymptomatic patients (Otto et al., 1997).
To date, there is no cure to CAVD and treatment solely depends on surgical
replacement of the stenotic valve via open cardiac surgery or transthoracic valve
replacement approaches (Hulin, Hego, Lancellotti, & Oury, 2018; Hutcheson,
Aikawa, & Merryman, 2014). However, surgical replacement is not a definitive cure
and patients can develop acute and chronic complications after surgery including:
hemolysis, aortic pseudoaneurysm and dissection, paravalvular leakage,
retraction of aortic valve leaflets, aortic valve insufficiency, endocarditis, and
obstruction (Pham et al., 2012). Unfortunately, bioprosthetic valves tend to calcify
in a significant number of patients and may eventually require replacement.
Additionally, the physical structure of the mechanical valve prosthesis promotes
thrombosis and requires concurrent long-life anticoagulant therapy (Bonow, Leon,
Doshi, & Moat, 2016; J. M. Brown et al., 2009; Hermans et al., 2013). These results
indicate that surgery provides only a temporary fix for CAVD symptoms while the
search for alternative medical therapy should be considered to treat or stop the
disease progression and improve the patient’s survival.
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2.1.5 The role TGFβ1 and Klotho in CAVD development and progression,
insight from clinical, in vivo and in vitro studies
TGFβ1 is a member of polyfunctional cytokines and one of the earliest
ligands to be detected maintaining its expression throughout heart morphogenesis
(Doetschman, Barnett, et al., 2012; Molin et al., 2003). During early heart
development, Tgfb1 is expressed by the vascular endothelium, the endocardium
of OFT and AVC, the endocardium lining the trabecular myocardium, and the
cushion mesenchymal cells (E9.5-E12.5) (Doetschman, Barnett, et al., 2012; Molin
et al., 2003).

After valve leaflets are differentiated or matured, Tgfb1 is

continuously expressed by the overlying endocardium and vascular endothelium
(E13.5-E15.5) (Molin et al., 2003). Augmented TGFβ1 and the downstream
SMAD3 signaling have been reported in human patients with CAVD (Jian et al.,
2003; Schlotter et al., 2018). Jian et al. conducted histopathological studies
comparing the levels of TGFβ1 in aortic valve tissues obtained from patients with
CAVD and normal aortic valve tissues obtained from autopsy controls (Jian et al.,
2003). This study showed that both latent and active TGFβ1 was highly expressed
within the VICs and the extracellular matrix of calcified valves compared to only
focal expression of TGFβ1 within the VICs of healthy valves (Jian et al., 2003).
The same study also showed that in vitro culture of sheep aortic valve interstitial
cell treated with TGFβ1 form nodule-like aggregates which underwent calcification
in a time-dependent manner (Jian et al., 2003). Similarly, Osman L et al. (2006)
reported that human valve interstitial cells (VICs) can differentiate into osteoblastlike cells in vitro in the presence of several mediators, including Tgfb1, which leads
to increased alkaline phosphate expression and activity(Osman, Yacoub, Latif,
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Amrani, & Chester, 2006). Besides, pharmacological treatment with atorvastatin
was able to reduce all the potential osteogenic mediators, including Tgfb1, and
reduce ALP in VICs cells (Osman et al., 2006). Furthermore analysis of aortic valve
tissues obtained from patients with calcific aortic stenosis, using transcriptomics
and proteomics modalities, revealed the involvement of TGFβ signaling and PSMAD3, the downstream transducer of TGFβ ligands, in the pathogenesis of
CAVD (Schlotter et al., 2018). However, the mechanism by which TGFβ1 leads to
CAVD is unknown.
Klotho is a multifunction’s transmembrane protein with anti-aging properties
(Xu & Sun, 2015). The Klotho (KL) gene is located on the long arm of chromosome
13 (chromosome 13q12) of the human genome and encodes the α-Klotho protein
(Matsumura et al., 1998; Xu & Sun, 2015). Klotho is a transmembrane protein with
a long extra cytoplasmic domain, transmembrane domain, and intracellular domain
(Kuro-o, 2011). It is expressed mainly by the tubular epithelial cells of the kidney
where the membrane bound klotho interact with the fibroblast growth factor
receptor (FGFR) and create binding sites for the FGF23 ligand for two main
purposes: first, to suppress vitamin D synthesis, second, to enhance phosphate
secretion (Consortium, 2000; Doi et al., 2011; Kuro-o, 2011; Kuro-o et al., 1997;
Shimada et al., 2004). On the other hand, the extracellular domain can be cleaved
by α or β secretases enzymes and circulated in the blood stream as the secreted
klotho, which exert different biological actions in various organs independent on
FGF23 (Doi et al., 2011; Kuro-o, 2011).
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The Klotho loss of function mutation in mice results in a premature aging
syndrome characterized by infertility, atrophy of the skin, osteoporosis,
emphysema and a short life spine (Kuro-o et al., 1997). Within scope of
cardiovascular diseases, Klotho knockout mice exhibit a non-inflammatory calcific
aortic valve disease characterized by endochondral calcification of the aortic valve
hinge region (Gomez-Stallons, Wirrig-Schwendeman, Hassel, Conway, & Yutzey,
2016). In contrast, overexpression of klotho in mice has antifibrotic effects and
inhibits EMT-mediated cancer metastasis in athymic xenografts and kidney fibrosis
induced by ureter obstruction in mice (Doi et al., 2011). This particular study
suggests that the antifibrotic effect of klotho was due to the binding of klotho to the
TGFβ receptor 2 which in turn competes and inhibits Tgfb1 binding and Tgfb1induced EMT (Doi et al., 2011). Similarly, knockout of klotho in adipose stem cells
reduces their proliferation and differentiation, while overexpression of Klotho in
these cells rescues the phenotype via inhibition of Tgfb1 and the downstream
Smad2/3 (Fan & Sun, 2016). Taken together, these studies suggest a potential
link between TGFβ1 overexpression and CAVD, however, most of the TGFβ1
mechanisms were tested in vitro, with little clarification about whether the
increases in TGFβ1 promotes CAVD or aim to restore valve morphology and
function. In some cases, prior studies even suggest a contradictory role of Tgfb1
and secreted klotho. Overall, their interaction in pathogenesis of CAVD have not
been sufficiently delineated. In the present study, we will confirm and extend our
findings which indicate that augmented TGFβ1 signaling in the cushion
mesenchyme-derived VICs causes the onset and progression of calcific aortic
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valve disease. We will test if the overexpression of Tgfb1 in the cushion
mesenchyme-derived VICs, via Smad3, causes CAVD. Then we will identify if
increased Tgfb1 signaling in the cushion mesenchyme-derived VICs causes
CAVD via regulation of the secreted Klotho protein.
2.2 MATERIALS AND METHODS:
2.2.1 Mice: All animal work was performed in accordance to protocol approved by
the Institutional Animal Care and Use Committee (IACUC) at University of South
Carolina. All mice either available in the Azhar laboratory or were obtained from
JAX lab. The following mice were used in this study: Tgfb1Tg, Postn-Cre Tg, Tgfb1+/, Smad3+/-, Klotho+/-, Nfatc1-Cre, and Wnt1-Cre2.
Tgfb1Tg, Postn-Cre

Tg

were generated by breeding Tgfb1Tg female mice,

harboring a constitutively active Tgfb1 transgene, to Postn-CreTg male mice which
express Cre recombinase in the cushion mesenchyme-derived valve interstitial
cells (Figure 2.5). Tgfb1Tg; Postn-CreTg; Tgfb1+/- mice were generated via two
breeding steps (Figure 2.6). First, Tgfb1+/- females were mated to Tgfb1Tg male
mice to generate Tgfb1+/-; Tgfb1Tg, second, Tgfb1+/-; Tgfb1Tg females were mated
to Tgfb1Tg; Postn- Cre

Tg;

male. Similarly, Tgfb1Tg; Postn-Cre

Tg;

Smad3+/- mice

were generated via two breeding steps (Figure 2.6). First, Tgfb1Tg females were
mated to Smad3+/- males to generate Tgfb1+/-; Smad3+/- mice, Second, Tgfb1Tg;
Smad3+/- females were mated to Tgfb1Tg; Peri Cre Tg males.
Klotho

-/-

mice were generated via breeding Klotho+/- males to Klotho+/-

females. While Klotho -/-; Smad3+/- mice were generated via two breeding steps
(Figure 2.7): First, Klotho+/- females were mated to Smad3+/- males to generate
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Klotho+/-; Smad3+/- mice, second, Klotho +/-; Smad3+/- males were crossed to Klotho
+/-;

Smad3+/- females.
Tgfb1Tg; Nfatc1-CreTg mice (Figure 2.8) were generated by breeding

Tgfb1Tg female mice to Nfatc1-Cre

Tg

male mice which express Cre recombinase

in the endocardial cell lineage. Tgfb1Tg; Wnt1-Cre2Tg mice (Figure 2.9) were
generated by breeding Tgfb1Tg female mice to Wnt1-Cre2Tg male mice which
express Cre recombinase in the neural crest cells. Genotyping was performed via
PCR reaction performed on phenol extracted DNA samples obtained from tails
tissue.
2.2.2 Histological staining: Morphological examination was assessed using
Hematoxylin-Eosin and Movat’s Pentachrome stains. Detection of calcium
deposits was performed using Alizarin Red staining. Collagen was detected using
Masson’s Trichrome and Picrosirius Red stains. Proteoglycan content was
assessed using Alcian blue staining. All Staining were performed according to the
manufacturer’s protocols (American Master Tech, Inc). Tissue processing was
performed as follows: adult and embryonic hearts were perfused in 1xPBS, fixed
in 4% paraformaldehyde for 24-48 hours followed by 3 rinses in 1xPBS. Tissues
were dehydrated in 3 gradients of alcohol concentrations 70%, 95%, 100%,
cleared in 3 changes of xylene, and embedded in paraffin in a vacuum oven at 60
ºC. Serial sections were performed using a Leica microtome and standard
sectioning involved the entire aortic valve, the entire mitral valve, part of the left
ventricles and part of the ascending aorta. For the Hematoxylin-Eosin staining,
tissue sections were deparaffinized in Xylene (3 changes x 5 minutes), rehydrated
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in gradients of ethanol 100%, 95%, 70% (2 changes x 3 minutes) followed by
rinsing in distilled water. Sections were stained with hematoxylin for 5 minutes
followed by washing in running water for 5 minutes. Hematoxylin was turned blue
by dipping slides in freshly prepared Scott's tap water substitute for 30 seconds
followed by washing in distilled water. Sections were dipped in 95% alcohol for 3
minutes stained with eosin for 3 minutes, dehydrated in 70%,95%,100% alcohol,
cleared in xylene, and mounted with permount mounting media. For the Movat’s
Pentachrome Staining, tissue sections were deparaffinized and rehydrated as
previously described. Sections were first stained for 15 minutes in Verhoeff’s
elastic stain prepared freshly by mixing an equal volume of 10% Absolute alcoholic
hematoxylin, 10% Ferric Chloride, and Universal Iodine. After washing in deionized
water, slides were dipped in 2% Ferric Chloride for 1 minute then rinsed in
deionized water. Slides were then immersed in 5 % Sodium Thiosulfate for 1
minute then rinsed in deionized water. Stain for mucins was performed by dipping
slides in 3% acetic acid followed by immersion in 1% Alcian blue solution for 15
minutes then rinse in deionized water. Slides were then incubated in Crocein
Scarlet-Acid Fuchsin for 2 minutes and rinsed in deionized water and dipped in 1%
acetic acid. Connective tissue was differentiated by immersing slides in 5%
Phosphotungstic acid for 4 minutes followed by dipping in 1% Acetic acid. For
collagen staining, slides were dipped in absolute alcohol for 2 minutes followed by
immersion in Saffron solution for 15 minutes. Finally, slides where dehydrated in
100% ethanol, cleared in Xylene and mounted with Permount Mounting Medium.
For the Alizarin Red Staining, tissue sections were deparaffinized and rehydrated
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as previously described. Sections were then dipped in Alizarin red solution for 5
minutes, Acetone for 20 seconds, 50% Acetone-Xylene for 20 seconds, cleared in
Xylene and mounted in Permount Mounting Medium. Staining was performed on
serial aortic valve sections (3 sections apart) and images were acquired using
E400 Nikon Optiphot microscope and Alizarin Red positive calcification areas per
section were quantified using image pro plus software. For the Alcian Blue
Staining, sections were deparaffinized and rehydrated as described previously
followed by dipping in an Alcian blue stain for 30 minutes. After washing in distilled
water, the nuclei were counterstained with nuclear fast red stain for 5 minutes,
washed in distilled water, dehydrated in 70%, 95%, 100% alcohol, cleared in
Xylene and mounted in Permount Mounting Medium. For the Masson’s
Trichrome Staining, tissue sections were deparaffinized and rehydrated as
described previously and fixed in Bouin's solution for 30 minutes at 60 ºC. After
rinsing in distilled water, sections were stained in freshly prepared Weigert's
working solution for 10 minutes followed by rinsing in running water for 15 minutes.
Sections were then stained in Biebrich scarlet-acid fuchsin solution for 20 minutes,
rinsed in distilled water, differentiated in phosphotungstic acid solution for 20
minutes, dipped in aniline blue solution for 10 minutes, rinsed in distilled water and
differentiated briefly in 1% acetic acid 5 minutes. After washing in distilled water,
sections were dehydrated in 95% and 100% alcohol, cleared in xylene and
mounted in Permount Mounting Medium. For the Picrosirius Red Staining,
sections were deparaffinized and rehydrated as described previously and the
nuclei were counterstained with freshly prepared Weigert’s hematoxylin solution
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for 5 minutes followed by washing under running water. Sections were then dipped
in picrosirius red stain for one hour followed by washing in water. Sections were
dehydrated in 100% alcohol, cleared in xylene and mounted in Permount Mounting
Medium. Images were obtained using EVOS imaging system.
2.2.3 TUNEL assay: Apoptosis was detected using FragEL™ DNA Fragmentation
Detection Kit, Colorimetric - TdT Enzyme Cat#QIA33, following the manufactures
protocol. Briefly, sections were deparaffinized in xylene (3 changes x 5 minutes),
rehydrated through a gradient in alcohol concentrations 100%, 95%, 80%, 70% (2
changes x 3 minutes) followed by an immersion in 1xTBS (2 changes x 5 minutes).
Sections were permeabilized using 1% Proteinase K in Tris buffer for 15 minutes
at room temperature. After washing in 1xTBS, endogenous peroxidase was
inhibited with 30% H2O2 – Methanol (1:10 dilution) for 5 minutes at room
temperature followed by immersion in 1xTdT Equilibration Buffer for 30 minutes at
room temperature. To mark apoptotic cells, sections were incubated in TdT
Labeling Reaction Mixture (contains the terminal deoxynucleotidyl transferase TdT
Enzyme) in a humidified incubator for 1 hour at 37°C. After 3 washes in 1xTBS,
the reaction was terminated by immersion of slides in a stop buffer for 5 minutes
followed by 3 washes in 1xTBS. To detect the signal, sections were immersed in
a blocking buffer for 5 minutes, incubated with 1x conjugate in blocking buffer for
30 minutes at room temperature, rinsed in 3 changes of 1xTBS, and incubated
with freshly prepared DAB solution. Nuclei were counterstained with methyl green
and sections were mounted with Permount Mounting Media. Images were obtained
using a Nikon E400 light microscope with 4x objective. Quantification of percent
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apoptosis per area measured was performed using Image Pro Plus software as
follows: first an area of interest was drawn surrounding the OFT cushion and used
constantly for all sections measured, the percent of apoptosis was averaged from
3 corresponding sections per animal with total of 3 experimental (double
transgenic) and 3 littermate control embryos were included.
2.2.4 Immunohistochemistry and immunofluorescence:

Sections were

deparaffinized in xylene (4 changes X 10 minutes), rehydrated in a gradient of
alcohol 100%, 95%, 70% (3 changes x 5 minutes) and rinsed in distilled water (2
changes x 5 minutes). Heat induced antigen retrieval was performed using a
Citrate-based buffer (pH 6.0) for 15 minutes followed by washing in distilled water
(3 changes x 5 minutes). Blocking of non-specific binding were performed using
either 2.5% horse serum for immunofluorescence or double-enzyme-block for
immunohistochemistry. Sections were incubated overnight at 4 deg C with the
following antibodies: Anti-Cd68, Anti-cardiac muscle actin (HHf35) , anti- aggregan
anti-periostn, anti- p-histone, anti-HA tag. After washing with 1xPBST (4 changes
x 10 minutes), signals were detected as follows: Vectastatin ABC kit or VectaFluor
double labeling kit Dylight 488 anti-rabbit, Dylight 594 anti-mouse IgG according
to the manufacturer’s protocol.
2.2.5 Tgfb1 RNA scope in situ hybridization: All kits and RNA probes were used
from Advanced Cell Diagnostic, Inc: RNAscope® 2.5 HD Reagent Kit-BROWN,
cat# 322300). Detection of Tgfb1 expression in Tgfb1tg; Nfatc1-cre tg E11.5 was
performed using Tgfb1 probe and RNAscope® 2.5 HD Detection Reagent –
BROWN. Initially slides were dried in oven at 60C for 1 hour, sections were
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deparaffinized in xylene (3 changes) followed by dipping in 100% alcohol (two
changes). Tissues were incubated with hydrogen peroxide for 10 minutes then
rinsed in distilled water. Target RNA scope pretreatments were performed by
immersion of the slides in heated Target retrieval solution for 15 minutes followed
by washing in distilled water then dipping in 100% alcohol. Tissue permeabilization
were performed by incubation of the sections with protease plus solution at 40 deg
C for 15 minutes followed by washing in distilled water.

Tissues were then

hybridized with a Tgfb1 probe for 2 hours at 40 deg C, rinsed in washing buffer,
and hybridized with a set of 5 amplifiers. After rinsing in washing buffer, signals
were detected using brown chromogenic reagents. Slides were mounted, and
images were obtained using the Nikon E400.
2.2.6 TGFβ receptor 1 kinase inhibitor (SB431542) treatment: 12 days-old mice
were injected intraperitonially with TGFβR1 or ALK5 kinase inhibitor (SB431542)
(10mg/kg or 15mg/kg) or DMSO on alternate days (3 doses per week) for 5 weeks.
Mice were sacrificed by 8 weeks of age and hearts were collected, fixed in 4%
paraformaldehyde and prepared for tissue processing and sectioning as previously
described. Alizarin Red staining was performed on serial sections (21 microns
apart) of the entire aortic valve. Sections were imaged using the Nikon E400 and
Image pro plus software used to quantify the calcified tissue (Alizarin red positive
area in um2) performed in the treated double transgenic mice compared to vehicle
double transgenic and the wild type controls.
2.2.7 AMIRA 3D reconstruction: serial sections of the aortic valve for 1-year
control and double transgenic were imaged using a 4x objective on the Nikon E400
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microscope. Similarly, serial sections of the whole hearts of the Tgfb1Tg, Nfatc1Cre Tg and littermate controls were imaged at 4x. Tiff images were loaded into the
AMIRA software and aligned manually. Segmentation was performed using the
Lasso tool to manually trace the boundaries of the aortic valve leaflets or the heart
and endocardial cushions on each section followed by a reconstruction of the 3D
image. Cushion volume was measured using the material-stat tool. The surface
was smoothed, and the images were saved and exported as Tiff files.
2.2.8 Microarray analysis: the aortic valve region was micro-dissected from 8
months-old mice (4 male controls, 4 males double transgenic, 4 female control, 4
females double transgenic) and saved in RNA later solution at -20c until day of
analysis. Total RNA extraction, Bioanalysis of RNA samples, and Microarray
experiments (Applied Biosystems platform), and data analysis were performed by
Dr. Diego Altomare in the Functional Genomics Core at the USC College of
Pharmacy.
2.2.9 Statistical analysis: Statistical analysis for two groups comparison was
performed using unpaired Student t-test. One-tailed P-values of 0.05 were
considered significant. Error bar represented the standard deviations (SD) for the
groups. GraphPad InStat was used to perform all statistical analysis
(www.graphpad.com).
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2.3 RESULTS
2.3.1 Tgfb1 overexpression causes cartilage nodule formation in the aortic
hinge region of Tgfb1Tg; Postn-Cre Tg at birth
To confirm the role of augmented TGFβ1 in the pathogenesis of CAVD and
to further extend the earlier findings, we generated a transgenic mouse model,
Tgfb1Tg; Postn-Cre

Tg,

by genetic intercrossing, in which the overexpressed

bioactive-TGFβ1 is driven by the 3.9 Postn promoter expressed by the cushion
mesenchymal derived-VICs (Figure 2.5). Histological analysis was performed on
serial sections of the aortic valve tissues obtained from the transgenic mice and
the littermate controls at P0. Morphological examination confirmed the
spontaneous formation of avascular nodule-like aggregates of mesenchymal cells
in the aortic hinge region of the transgenic mice. These aggregates were located
between the attachment of the left and right coronary leaflets to the annulus and
extended to the aortopulmonary septum (Figure 2.10). These cells exhibit features
of chondrocyte-like morphology in which cells are located in lacuna and are
surrounded by a homogenous matrix. The homogenous matrix is darkly stained by
Alcian blue indicating its high proteoglycan content. Furthermore, the
mesenchymal cells of the localized nodular area showed overexpression of HAtagged bioactive TGFβ1 marked as brown dots (Figure 2.11), while no calcification
in the aortic valve was detected.
2.3.2 Tgfb1 overexpression induces endochondral ossification and multiple
nodule formation in the aortic valves of Tgfb1Tg; Postn-Cre Tg mice
Histological follow-up of the aortic valve at 1 month of age in both male and
female transgenic mice (Figure 2.11) confirmed the endochondral-like ossification
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of the nodular area (bone develop from cartilage intermediate). Calcification was
confined to the nodular area until 1 year of age when multiple calcific nodules
developed at the aortic hinge region (Figure 2.12). Furthermore, temporal disease
progression and the extent of calcification were different between male and female
mice. Transgenic males showed multiple calcific nodules at the hinge region with
the formation of new cartilage-like nodules that span and distort the right and left
cusps (Figure 2.13). In contrast, females tended to have smaller and solitary
calcific nodules at the hinge region which did not extend to the leaflet itself (Figure
2.14). Altogether, these results indicate that increased levels of bioactive-TGFβ1
is a potent driver of CAVD initiation and progression.
2.3.3 Valve thickening was more severe in transgenic males compared to
females
Histological (Trichrome) and immunofluorescence (aggrecan and periostin)
staining were performed on serial sections of the aortic valve area (Figure 2.15).
The qualitative data suggested marked collagen deposition in the hinge region and
in the cusps of Tgfb1Tg; Postn-Cre

Tg

compared to controls. Furthermore, higher

expression levels of both aggrecan and periostin were detected in the diseased
cusps of Tgfb1Tg; Postn-Cre

Tg

mice particularly in the left and right leaflets.

Picrosirius red visualized under the light microscopy suggested more collagen
deposition in the leaflet and the nodular areas of Tgfb1Tg; Postn-Cre Tg male mice
compared to controls (Figure 2.16 and 2.17). In contrast, female mice show no
significant differences in valve thickening compared to controls and the fibrosis
was confined to the nodular area (Figure 2.17 and 2.18). Immunohistochemical
analysis of aortic valve tissues using anti-CD68 obtained from 3 male transgenics
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and 3 controls suggested no obvious macrophage infiltration (only a few cells were
CD8 positive) (Figure 2.22).
2.3.4 Fibrocalcific changes are associated with aortic valve leaflet fusion and
aortic stenosis in Tgfb1Tg; Postn-Cre Tg mice.
Early histological analysis of Tgfb1Tg; Postn-Cre Tg mice show that the aortic
valve has three nearly equal sized cusps that anchored separately to the annulus
(Figure 2.19) Histological analysis of 1-year old mice showed extensive fibrocalcific
changes at the hinge and base regions of the leaflets with partial fusion of two
adjacent leaflets into a raphe (seam-like fusion) with severe narrowing of the aortic
valve lumen, resembles aortic valve stenosis, and dilation of aortic root in the
double transgenic male mice (Figure 2.20). Amira 3D reconstructions of serial
sections of the whole aortic valve region show that all mice with an incomplete
raphe have left and right coronary leaflet fusion (Figure 2.21). One mouse actually
presented with an additional left coronary and non-coronary union resulting in a
potentially uni-cuspid valve. On the other hand, only one of transgenic female mice
developed partial left and right coronary leaflets fusion with very short raphe, while
none of the female mice developed aortic stenosis (Figure 2.20).
2.3.5 Atrial myxoma is seen in Tgfb1Tg; Postn-Cre Tg mice
Three double transgenic mice (two males, one female) developed large
well-defined solid masses on the left atria (Figure 2.25). These results suggest that
Tgfb1 has a wide spread cardiac effect particularly in transgenic male compared
to non-transgenic mice.
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2.3.6 Microarray analysis of the aortic valves of Tgfb1Tg; Postn-Cre Tg mice
showed increased calcification and cartilage promoting genes in both male
and female Tgfb1Tg; Postn-Cre Tg mice:
Microarray analysis was performed on RNA samples obtained from aortic
valve tissues and periaortic area of 8 months-old male and female double
transgenic mice and littermate controls (16 mice, 4 per group) (Figure 2.23). Of
note, the result revealed higher expression levels (approximately 14 folds) of the
osteogenic gene Secreted Phosphoprotein 1 (SPP1) and the chondrogenic gene
Chitinase 3 like 1 (CHI3L1) supporting the endochondral calcification observed in
the double transgenic mice. These results also show differential gene expression
between male and female double transgenics with only the above two genes
mutually upregulated in both groups.
2.3.7 Pharmacological and genetic inhibition of Tgfb1 signaling attenuate the
calcification in Tgfb1 Tg; Postn-Cre Tg mice
To test whether inhibition of TGFβ signaling inhibits CAVD development
and or progression of Tgfb1

Tg;

Postn-Cre

Tg

mice and littermate controls were

treated with TGFβ receptor 1 (SB431542) inhibitor or DMSO and subjected to
histological analysis to detect the calcification. Preliminary data using Alizarin red
staining of serial sections (21µm apart) of the aortic valve showed that
pharmacological inhibition of TGFβ signaling attenuated the calcification in the
transgenic mice compared to DMSO-treated transgenic controls which require
further confirmation with larger sample size (Figure 2.33). Similarly, to genetically
reduce TGFβ1 signaling and to test whether it will rescue CAVD in the transgenic
mice, we generated a Tgfb1Tg; Postn-Cre

Tg

; Tgfb1+/- mice. These mice were

scarified by 8 weeks of age and Alizarin red staining performed on serial sections
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(21 µm apart) of the aortic valves. The preliminary results showed that the total
area of calcification was reduced in 2/3 of Tgfb1Tg; Postn-Cre Tg ; Tgfb1+/- compared
to transgenic controls which require further confirmation with larger sample size.
2.3.8 TGFβ1 overexpression attenuates apoptosis in outflow tract cushion
mesenchymal cells in Tgfb1Tg; Postn-Cre Tg mice.
Apoptosis and myocardialization are important remodeling mechanisms
governing the differentiation of endocardial cushions into heart valves and septa.
Apoptosis commonly occurs in cardiac cushions derived from endocardial and
neural crest cells and is usually followed by myocardialization of the endocardial
cushions in which cushion mesenchymal cells are replaced by cardiomyocytes. To
further understand the mechanisms that contribute to CAVD in Tgfb1Tg; Postn-Cre
Tg

mice, TUNEL staining was performed on alternate sections of the OFT at E13.5

transgenic and littermate control embryos (Figure 2.26). Results showed that
apoptosis was distributed mainly at the periphery of the OFT cushions in
transgenic mice while it involved the center of the cushion in the littermate controls.
Morphometric analysis showed that apoptosis was significantly reduced in
transgenic mice compared to littermate controls. Further hematoxylin and eosin
staining performed on E17.5 embryonic hearts show that the OFT cushions in
transgenic mice escaped apoptosis and surviving cells presumably formed nodulelike aggregates at the hinge region of the aortic valve with failure of
myocardialization at this area compared to controls. These results suggest that
TGFβ1 overexpression attenuates apoptosis in the OFT cushion mesenchyme and
contributes to the development of CAVD in Tgfb1Tg; Postn-Cre Tg mice.
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2.3.9 Conditional overexpression of TGFβ1 in the endocardial cells lineages
leads to formation of double outlet right ventricle (DORV)
Tgfb1 is expressed by cushion mesenchymal cells in endocardial cushions
during outflow tract formation and remodeling. To test whether augmented TGFβ1
signaling in endocardial derived-VICs leads to CAVD, we generated Tgfb1Tg;
Nfatc1 Tg mice in which bioactive TGFβ1 is driven by a Nfatc1 promotor expressed
by endocardial cell lineages (Figures 2.27,2.28, 2.29, 2.30, 2.31). Gross
comparison showed no obvious differences in the size and morphology of
transgenic mice compared to littermate controls. The bioactive TGFβ1 expression
was detected in the endocardium and endocardial-derived cushion mesenchyme
using anti-HA-tag immunohistochemistry, while, the total Tgfb1 (endogenous and
transgenic) was detected using RNA scope in situ hybridization. Follow-up
histological analysis and AMIRA 3D reconstructions at E11.5-E13.5 on serial
sections showed that overexpression of TGFβ1 in the endocardial cell lineages led
to alignment defects with formation of double outlet right ventricle (Fig. 3A, B).
Collectively, these early findings suggest that endocardial-derived TGFβ1 is critical
for OFT cushion alignment, however, it did not lead to nodule formation as seen in
Tgfb1Tg; Postn-Cre

Tg

mice suggesting different cell lineages contribute to CAVD

development.
2.3.10 Increased Tgfb1 signaling in neural crest-derived VICs leads to
cartilage nodule formation similar to Tgfb1Tg; Postn-Cre Tg mice
Neural crest cells are migratory stem-like cells that differentiate into multiple
cell types during embryonic development and give rise to peripheral ganglia,
smooth muscle, facial skeleton, and connective tissue, and other tissue (Motohashi
& Kunisada, 2015). Cardiac neural crest cells (CNCs) are a subset of neural crest
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cells that migrate during heart development to populate the distal OFT cushion and
contribute to aorticopulmonary septation and aortic valve development (Neeb,
2013) .We generated Tgfb1Tg; Wnt1-CreTg which expresses the bioactive Tgfb1
under control of the WNT1 promotor in the neural crest cell lineages, including
CNCs (Figure 2.32). Embryos were collected from different time-points including
OFT cushion formation (E12.5), remodeling (E16.5), and maturation (P0). Gross
morphological examination showed that all transgenic mice were smaller in size
and developed severe craniofacial malformations. Histological analysis of serial
sections of the aortic valve region at P0 showed cartilage-like nodule formation in
transgenic mice at the aortic hinge region between the left and right leaflets similar
to Tgfb1Tg; Postn-Cre

Tg

mice, however, Tgfb1Tg; Wnt1-Cre

Tg

die prenatally or at

birth which preclude further morphological analysis. Additional cell proliferation
and apoptosis would be required at E12.5 and E16.5 to determine the mechanisms
by which Tgfb1 reprogramed neural-crest derived mesenchyme cells leads to
cartilage nodule formation.
2.3.11 Heterozygous loss of Smad3 in klotho knockout mice didn’t prevent
calcification development
Although Klotho is known to cause CAVD in mice and is a competitive
inhibitor to TGFβ1 in other diseases, the molecular interaction between the two in
CAVD development and progression have never been fully tested. To test the
hypothesis that TGFβ1 causes CAVD via inhibition of the secreted Klotho protein,
we generated Klotho-/-; Smad3+/- and littermate Klotho+/+; Smad3+/- controls.
Alizarin red staining was performed on paraffin sections of the aortic valve area of
6 weeks-old mice to determine whether the knockout of TGFβ1 signaling via
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Smad3 can rescue the CAVD phenotype in Klotho mice. Preliminary data
suggested that Klotho-/-; Smad3+/- developed calcification at the hinge region and
that reduction of Smad3 signaling in Klotho mice did not inhibit calcification,
however, further analysis is needed to score and quantify the calcification area in
Klotho-/-; Smad3+/- compared to Klotho-/- , and to determine if Tgfb1 via Smad3
reduces the progression of aortic valve calcification.
2.4 DISSCUSSION
Calcific aortic valve disease (CAVD) is a global health burden rapidly
increasing as the aged population continues to grow (Nishimura et al., 2014;
Yutzey et al., 2014). Abundant clinical evidence as well as in vivo and in vitro
studies suggest that CAVD develops overtime in response to a significant number
of well-regulated molecular events, which underlie the pathogenesis of aortic valve
calcification and its progression to aortic valve stenosis (Rajamannan et al., 2011).
VICs activation, calcification, and fibrosis are the hallmarks of CAVD and these
can be induced by various exogenous and endogenous mechanisms, for example:
endothelial damage and lipid accumulation, inflammation and extracellular matrix
remodeling, and cytokines dysregulation (Leopold, 2012). Among these cytokines,
TGFβ1 overexpression has been linked to CAVD in humans, while in vitro studies
further confirmed the critical role of TGFβ1 in VICs activation and calcification (Jian
et al., 2003). However, the role of TGFβ1 in development of CAVD in vivo remains
largely unknown due to the diverse, and sometime contradictory, physiological
actions of the TGFβ signaling in regulating tissue homeostasis (Morikawa et al.,
2016). We have previously found that TGFβ1 causes CAVD in vivo. To further
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confirm and extend these findings, we performed rigorous histological
characterization of tissue specific transgenic mouse model, Tgfb1Tg; Postn-Cre
Tg

mice, which overexpressed bioactive TGFβ1 in the cushion mesenchymal-

derived VICs. A follow up study was conducted at different ages up to one-year to
test the effect of augmented Tgfb1 signaling on the development and progression
of CAVD in the double transgenic model compared to age and gender matched
controls (E13.5 to12 months).
Our results confirmed our previous findings and indicate that Tgfb1 causes
calcific aortic valve disease in double transgenic mice. Endochondral bone
formation is a sequential process in which bone develops from preformed cartilage
and it is one of the main types of calcification seen in human CAVD (Freeman &
Otto, 2005; Mohler et al., 2001). TGFβ1 is a potent regulator of mesenchymal cells
condensation,

chondrocyte

differentiation,

and

ossification

during

bone

development (G. Chen, Deng, & Li, 2012). In vivo studies have showed that Tgfb1
is the driving force for ectopic bone formation in non-osseous tissues (Tachi et al.,
2011; X. Wang et al., 2018). Similarly, TGFβ1 dysregulation has been thought to
be a potential trigger for CAVD in humans (Jian et al., 2003), however, the causal
link has never been established in vivo. Our results show that Tgfb1Tg; Postn-Cre
Tg

mice develop endochondral bone formation with VICs transformation. The

calcification initiates in the hinge region at the base of the leaflets and progresses
towards the tip along with VICs activation in the double transgenic mice.
Endochondral calcification is one of the critical processes underling the
development of CAVD in humans (Mohler et al., 2001; Mohler, Kaplan, & Pignolo,
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2012), hence, our mouse model is a good one for recapitulating this form of CAVD.
These results are consistent with in vitro data that TGFβ1 is a potent regulator of
VIC activation during both calcification and tissue injury. Clark-Greuel et al have
investigated the in vitro role of TGFβ1 in valve interstitial cell calcification and the
results show that supplementing Tgfb1 to the culture media of VICs results in
nodule formation and progressive calcification over the course of two weeks with
increased alkaline phosphatase production, cell apoptosis, and increased matrix
metalloproteinase 9 (MMP9) (Clark-Greuel et al., 2007). Furthermore, Liu &
Gotlieb showed that Tgfb1 expression was increased by injured VICs during in
vitro wound healing. They showed that adding TGFβ1 to the culture of wounded
VICs increases cell proliferation, stress fiber formation, and accelerates wound
closure (A. C. Liu & Gotlieb, 2008). Further analysis of the effect of Tgfb1 on VICs
proliferation, apoptosis, and myofibroblast transdifferentiating in Tgfb1Tg; PostnCre Tg mice are required to better understand the progression of this disease.
Our microarray data supports the observed endochondral calcification and
shows increased expression of both osteogenic and chondrogenic genes, namely,
Osteopontin and Chitinase 3 like 1, respectively. Increased expression of these
genes in age and gender-matched control and double transgenic animals will be
validated by qPCR. Osteopontin (OPN) is a secreted phosphorylated sialoprotein,
also known as Spp1 (Sodek, Ganss, & McKee, 2000). OPN is a multifunction
protein involved in EMT during embryonic development and wound healing and
fibrosis after tissue injury (Weber, Li, Wai, & Kuo, 2012). It is also a bone matrix
protein which is critical for bone mineralization via its two binding sites or motifs
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that facilitate hydroxyapatite binding, cell attachment, and cell signaling (Sodek et
al., 2000). OPN is highly expressed in aortic valve tissues and the plasma of
patients with calcific aortic stenosis. It is highly expressed in the cytoplasm of the
fibroblast-like VICs, (Grau et al., 2012; Kennedy et al., 2000; Mohler, Adam,
McClelland, Graham, & Hathaway, 1997), however the mechanisms that regulate
OPN expression in CAVD are not fully understood. TGFβ1 is known to regulate
OPN expression during bone formation, EMT, and cancer development (ElTanani, Platt-Higgins, Rudland, & Campbell, 2004; Janssens, ten Dijke, Janssens,
& Van Hul, 2005; Weber et al., 2012). Furthermore, OPN can be activated by TGFβ
signaling either directly, due to ability of SMAD3 to bind to OPN promotor, or
indirectly through activation of other osteogenic target genes, for example, Runx2
which can also bind to OPN promotor (Janssens et al., 2005; X. Shi, Bai, Li, & Cao,
2001; Stein et al., 2004). Although, our microarray data show a roughly 14-fold
increase in OPN expression in Tgfb1Tg; Postn-Cre

Tg

compared to controls, the

mechanisms by which Tgfb1 activate OPN and cause CAVD require further
investigation. Chitinase 3 like 1 (CHI3L1) is a human cartilage glycoprotein 39 (GP39) which lacks the enzymatic activity to hydrolyze chitin (N-acetylglucosamine)
(Di Rosa, Szychlinska, Tibullo, Malaguarnera, & Musumeci, 2014; Lee et al.,
2009). CHI3L1 plays multiple roles in cancer, chronic inflammation, and numerous
degenerative diseases (Di Rosa et al., 2014; D. H. Kim et al., 2018) and it regulates
TGFβ-mediated fibrosis and inhibition of apoptosis (Lee et al., 2009; Turn &
Kolliputi, 2014). Interestingly, a prior microarray study showed increased levels of
CHI3L1 in aortic valve tissue of patients with calcific stenosis, however, its role and
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mechanism of activation in CAVD are currently unknow (Bossé et al., 2009).
Comparatively, our microarray data showed a 14-fold increase in CHI3L1 in
Tgfb1Tg; Postn-Cre

Tg

compared to controls. Further studies are needed to test

whether CHI3L1 has SMAD binding element in the promotor region, and if serum
level of CHI3L1 positively correlates with CAVD progression which could be used
as a follow-up biomarker.
Valve thickening and fibrosis in CAVD occur due to an increase in the
production of extracellular materials by activated or transformed VICs (Dena Wiltz
& Blancas, 2013). The extracellular matrix composition in Tgfb1Tg; Postn-Cre

Tg

mice showed increased production of collagen, proteoglycan, and periostin in the
double transgenic mice. Increased ECM deposition forms a scaffold-like matrix for
the transformed VICs and the newly formed cartilage nodules that is similar to what
is seen during cartilage, bone or valve development (B. N. Brown & Badylak, 2014;
Gentili & Cancedda, 2009; Wirrig & Yutzey, 2013). Although Tgfb1 overexpression
in Tgfb1Tg; Postn-Cre Tg causes CAVD in both genders, the female mice showed
only a mild pathology. In female mice the calcification was localized, valves were
only slightly thicker, and no aortic valve stenosis was apparent. In contrast, agematched male mice showed more extensive aortic valve calcification, dramatic
valve thickening, left ventricular dilation, and these mice develop severe aortic
valve stenosis. These findings suggest that female mice have regulatory
mechanisms that serve to reduce the degenerative effect of TGFβ1 and prevent
CAVD progression to aortic valve stenosis. We speculate that these results may
be attributed, in part, to the antifibrotic role of estradiol E2 hormone, the
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predominate form of estrogen with strongest biological activity in premenopausal
females (Simpson, 2003). E2 is known to reduce myofibroblast proliferation and
migration and inhibit collagen deposition and fibrosis (Iorga et al., 2017). Further
analysis of older postmenopausal mice, injection with tamoxifen (estrogen
inhibitor), or oophorectomy in Tgfb1Tg; Postn-Cre

Tg

females’ mice could result in

fibrosis, valve thickening, and stenosis like their males’ counterpart.
Bicuspid aortic valves are the most common congenital heart defect in
human while the exact etiology remains poorly understood (George Tokmaji & Mol,
2013; Ward, 2000). BAV can also result from acquired damage and fusion of the
leaflets due to degenerative diseases in a pre-existing tri-leaflets valve (Ward,
2000). Histological analysis of Tgfb1Tg; Postn-Cre Tg mice suggest that these mice
are born with three nearly equal size leaflets and fusion of the leaflets occurs later
in life when the disease reaches an advanced stage (approximately 8 to 12 months
of age) and is secondary to the fibrocalcific degeneration of the leaflet and hinge
region. Analysis of old Tgfb1Tg; Postn-Cre

Tg

mice will establish if the raphe

formation increases with age and contributes to symptomatic aortic stenosis and
LV dysfunction.
Chronic Inflammation and infiltration of foam (lipid filled) and non-foam
macrophages have been reported in human CAVD (Otto et al., 1994). TGFβ1 and
TGFβ signaling is well known as a powerful inducer of macrophage infiltration and
polarization (Gentle et al., 2013; F. Zhang et al., 2016). Our preliminary
immunohistochemistry using the macrophage marker anti-CD68, suggests that the
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fibrocalcific changes in Tgfb1Tg; Postn-Cre

Tg

mice are independent on

macrophage infiltration.
Aortic valves are derived from multiple cell lineages, however, the role of
the heterogenous VICs population in CAVD is currently unknown. We first
performed a TUNEL assay to detect the apoptosis in cardiac cushions. Our data
show that OFT cushion mesenchymal cells resist apoptosis in Tgfb1Tg; Postn-Cre
Tg

embryos and these cells survive and condense into cartilage-like nodules that

calcified with age. To further validate if Tgfb1 have cell lineage-specific effects on
the development of CAVD, we generated two transgenic mouse models with
overexpression of Tgfb1 in the endocardial or neural crest-derived cushion
mesenchyme. Our results indicate that overexpression of Tgfb1 in neural crest and
not endocardial cushion derived-VICs cause cartilage nodule formation in the
aortic valve hinge region and this is similar to that seen in Tgfb1Tg; Postn-Cre

Tg

mice. These results suggest that augmented Tgfb1 signaling causes reprograming
of neural crest derived-VICs which contribute to the development and progression
of CAVD.
To establish a direct cause-and-effect relationship, we carried out rescue
experiments using pharmacological or genetic reductions of TGFβ signaling in
Tgfb1Tg; Postn-Cre

Tg

mice. Morphometric analysis of the aortic calcification

suggests that pharmacological inhibition and genetic reduction of Tgfb1 signaling
may slow disease progression in the long-term. Altogether the pharmacological
and genetic rescue experiments imply a cause-and-effect link between Tgfb1
overexpression and CAVD pathogenesis. Further analysis of the second group
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treated with a higher dose of TGFβ receptor I inhibitor or long-term therapy are
required to formulate a more meaningful conclusion.
Global Klotho knockouts in mice resulted in a non-inflammatory CAVD with
formation of calcific nodules at the hinge region of the aortic valve and had an
overlapping phenotype with Tgfb1Tg; Postn-Cre

Tg

mice. Next, we tested whether

the Tgfb1-dependent molecular input could be mediated through inhibition of
secreted klotho and we generated Klotho-/-/Smad3+/- and the littermate controls
(Klotho-/- and wild type). Histological analysis (Alizarin red) of 6 weeks-old mice
showed that reduction of Smad3 signaling did not inhibit calcification in theses
mice. However, further staining of the serial sections of these mice and a
morphometric analysis is necessary to quantify the calcification area per animal to
check whether reduction of Tgfb1 signaling via Smad3 partially attenuate the
disease progression. Alternatively, knockout of Smad2 in the klotho-/- could be
used to check whether the reduction of Tgfb1 via Smad2 not Smad3 would rescue
the CAVD phenotype.
Collectively, this study provides a comprehensive genetic and histological
characterization of up to one-year old Tgfb1Tg; Postn-Cre

Tg

mouse model. This

model spontaneously develops adult CAVD and raphe formation in response to
increased TGFβ1 and can be used to test novel diagnostic biomarkers and
therapies that can improve the survival of patients with calcific aortic valve
diseases in the future.
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Figure 2.1 Anatomy of the aortic valve. (A) Cross section showing the three
cusps of the aortic valve which are named based on their location to the
coronary arteries: the left coronary, the right coronary, and the non-coronary
leaflets. (B) Longitudinal section illustrating the main parts of the aortic leaflets,
aortic root, and the direction of blood flow from the left ventricle to the aorta
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Figure 2.2 Histology of the aortic valve. Schematic illustration of the aortic
valve structure, the outer layer is composed of a single row of endothelial cells
while the inner layers are composed of multiple layers of valve interstitial cells
(VICs) and stratified matrix layers including: the collagen-rich fibrosa,
proteoglycan-rich spongiosa, and elastin-rich ventricularis.
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Figure 2.3 Development of the aortic valve. Aortic valves initially develop
from acellular OFT endocardial cushions which are populated mainly by
endocardial and neural crest cell lineages via migration and EMT. Further
remodeling of the endocardial cushion leads to elongation and shaping of the
leaflets in which the extracellular matrix is organized into three distinct layers in
the mature leaflet.
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Figure 2.4 Types of Bicuspid Aortic Valves (BAV). True Bicuspid aortic
valves have two well separated leaflets with no raphe. Bicuspid valves with
fusion of the left and right leaflets or the coronary and the left or the right leaflets
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Figure 2.5 Generation of Tgfb1Tg; Postn-Cre Tg mice. Tgfb1Tg mice have the
Tgfb1 cDNA placed away from the promotor via an Egfp intervening sequence
and the gene is turned off. Postn-CreTg mice have a recombinase enzyme under
control of the Postn3.9 Kb promotor expressed by the cushion mesenchyme
derived VICs. Cre recombinase recognize LoxP sequences and delete the Egfp
sequence and the gene is turned on
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Figure 2.6 Tgfb1Tg; Postn-Cre Tg; Tgfb1+/- and Tgfb1Tg; Postn-Cre Tg;
Smad3+/- were generated to reduce Tgfb1 or Smad3 signaling,
respectively, in the transgenic mice
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Figure 2.7 Klotho-/- and Klotho-/-; Smad3+/- were generated to abolish
secreted klotho in the systemic knockout or to reduce Smad3 signaling in
the transgenic mice, respectively
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Figure 2.8 Generation of Tgfb1Tg; Nfatc1-Cre Tg mice. Nfatc1-Cre Tg mice
harbor the recombinase enzyme under control of Nfatc1 promotor expressed
by the endocardial cell lineage. Cre recombinase recognizes the LoxP
sequences and deletes the EGFB sequence and the transgene is turned on
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Figure 2.9 Generation of Tgfb1Tg; Wnt1-Cre2Tg mice. Wnt1-Cre Tg mice
harbor the recombinase enzyme under control of the Wnt1 promotor expressed
by neural crest cell lineage. Cre recombinase recognizes the LoxP sequences
and deletes the EGFB sequence and the transgene is turned on

62

Figure 2.10 WT and Tgfb1Tg; Postn-Cre Tg mice at P0. (A-B) Alcian blue
staining of the aortic valve of the transgenic mice and littermate control show
cartilage nodule formation in the hinge region of an aortic valve and the
aortopulmonary septa in Tgfb1Tg; Postn-Cre Tg mice. (C) Weight in grams show
no statistical differenced in normal birth weight between double transgenic and
littermate wildtypes N=6 (3 per group). (D) PCR genotyping of Tgfb1Tg; PostnCre Tg mice (# 4 and 5 are double transgenic mice while the rest are wild type
or single transgenic controls) (N=6, 3 per group)
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Figure 2.11 Endochondral calcification in both male and female Tgfb1Tg;
Postn-Cre Tg mice (P0-1 month). (A) H & E staining of P0 nodular area with
cartilage nodule formation (B) Alcian blue staining shows deposition of a
proteoglycan-rich matrix (C) HA-Tagged bioactive Tgfb1 is expressed by
transformed VICs (D) Alizarin red staining shows no calcification at P0 but (EF) significant calcification in 1-month male and female transgenic mice.
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Figure 2.12 Progressive calcification and multiple nodules formation at
the hinge region Tgfb1Tg; Postn-Cre Tg mice (P0-12 months). (A) Alizarin red
staining shows progressive calcification in transgenic mice. (B-C) Alizarin red
and (D) Alcian blue staining of aortic valves of 1 year-old wild type male mice
show a normal hinge region with no calcification (E-F) Alizarin red staining of 1year old double transgenic male show calcified nodules distorting the hinge
region and (G) Alcian blue staining shows the formation of a non-calcified
cartilage nodules near the base of the fused left and right leaflets
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Figure 2.13 CAVD progresses from the hinge region toward the tip of 1year old mice Tgfb1Tg; Postn-Cre Tg mice with no change in body weight.
(A-D) HA immunohistochemistry show HA tagged bioactive Tgfb1 is expressed
by activated VICs in the hinge region and the leaflet. (B-F) H and E and
Pentachrome staining shows progressive diseases with multiple cartilage
nodules in the body and the tip of the leaflet. (G) No difference in weight were
observed in the double transgenic mice compared to age and sex matched
controls P-value=0.293 and 0.159 for male and female groups, respectively
(N=22, 4-7 per group)
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Figure 2.14 Calcification is higher in 1-year old male Tgfb1Tg; Postn-Cre Tg
mice compared to age-matched double transgenic females. (A) Alizarin red
staining shows multiple calcified nodules in double transgenic male compared
to their female counterpart (B) morphometric quantification of the calcified area
in transgenic males and females are compared to wild type controls Pvalue=0.001 and 0.005 for male and female groups, respectively. P-Value =
0.003 for male dtg versus female dtg (N=3-5 per group)
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Figure 2.15 Increased fibrosis and extracellular matrix deposition in 1year-old Tgfb1Tg; Postn-Cre Tg mice. (A) Masson’s trichrome staining shows
increased collagen deposition in the leaflets and nodular area of double
transgenic mice compared to wild type controls (arrows). (B)
Immunofluorescence showed increased aggrecan and periostin deposition in
the leaflets and hinge region particularly within newly formed nodules (arrows)
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Figure 2.16 Valve thickening is higher in Tgfb1Tg; Postn-Cre Tg male mice
compared to age and sex matched wild type controls: (A-C) Picrosirius red
staining of wild type control males shows thin leaflets and wide aortic valve
lumens. (D-F) Picrosirius red staining of double transgenic males shows thicker
valves with significant collagen deposition (fibrosis) and narrowing of the aortic
valve lumen (stenosis). (G) Morphometric analysis shows increased surface
area of the aortic valve leaflet in double transgenic males compared to controls
(P-value=0.0231). (N=8, 4 per group)
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Figure 2.17 No differences in valve thickness or fibrosis in Tgfb1Tg; PostnCre Tg female mice compared to age and sex matched wild type controls:
(A-C) Picrosirius red staining of wild type control females show thin leaflets and
wide aortic valve lumens. (D-F) Picrosirius red staining of double transgenic
females show normal valve thickening, collagen content, and the aortic valve
lumen. (G) Morphometric analysis shows no difference in surface area of the
aortic valve leaflet in double transgenic females compared to controls. (N=8, 4
per group) (P-value=0.479)
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Figure 2.18 Tgfb1Tg; Postn-Cre Tg are born with tri-leaflet aortic valves
however, leaflets fusion develops around 8 months of age. (A-B) A trileaflet aortic valve is present in both wild type and double transgenic at P0.
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Figure 2.19 Increased Tgfb1 signaling causes raphe formation in 12
months-old Tgfb1Tg; Postn-Cre Tg mice. (A-F) Pentachrome and Alcian blue
staining show fusion of left and right aortic valve leaflets and long raphe
formation in the double transgenic males compared to separated tri-leaflet
valves in the wild type controls. (G-I) Pentachrome staining show fusion of the
non-coronary and left coronary leaflet in double transgenic male mouse
compared to the normal aortic valve in wild type control. (J-L) Pentachrome
staining show fusion of left and right coronary leaflet in double transgenic female
mouse compared to normal aortic valve in wild type control.
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Figure 2.20 Representative AMIRA 3D reconstruction shows different
types of aortic valve leaflets fusion in 12 months-old male Tgfb1Tg; PostnCre Tg mice. (A-D) Fusion of the left and right coronary leaflets with aortic
stenosis in the double transgenic mice compared to controls. (E-F) Fusion of
the left and right coronary leaflets and the left and non-coronary leaflets in a
double transgenic mouse with aortic stenosis compared to control.
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Figure 2.21 No marked CD68 positive macrophage infiltration. (A-F) AntiCD68 (macrophage marker) immunohistochemistry shows only a handful of
CD68 positive cells in double transgenic mice compared to wildtype control.
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A

B

Figure 2.22 Overexpression of Tgfb1 causes upregulation of osteogenic
and chondrogenic genes in aortic valve tissue of Tgfb1Tg; Postn-Cre Tg
mice: (A) differential gene expression (fold change 1.8, P-value 0.05) show
upregulation of CHIL3 like 1 kinase (chondrogenic gene) and Osteopontin
(osteogenic gene) in response to increases in Tgfb1. (B) Ven diagram shows
that male and female double transgenic mice show differential gene expression
but share upregulation of above mentioned two genes.
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Figure 2.23 Myxoma of the atria developed in 12 months-old Tgfb1Tg;
Postn-Cre Tg mice: (A) A heart of wild type control and (B) a heart of double
transgenic without myxoma. (C-D) Heart of a double transgenic mouse with
myxoma (Front and rear view). N=3 develops myxoma (2 males and 1 female
double transgenic).
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Figure 2.24 Cushion mesenchyme-derived VICs resist apoptosis and form
cartilage-like nodules in Tgfb1Tg; Postn-Cre Tg mice. (A-B) TUNEL ISH and
quantification of the OFT cushions show a reduction in apoptotic cells (E13.5)
and cartilage nodule formation (E17.5) in double transgenic compared to
controls ( P-value = 0.043) (c) Images of E13.5 embryos show no gross
morphological abnormalities of double transgenics compared to littermate
control (N=6, 3 per group).
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; Nfatc1-Cre tg :
(A-B) HA-Tagged in wildtype control (C-F) HA-Tagged Bioactive Tgfb1 expression
in the OFT cushion and endocardial derived cushion mesenchymal cells in E11.5
double transgenic embryos

Figure 2.25 HA-tagged Tgfb1 expression in the Tgfb1
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Tg

Figure 2.26 Tgfb1 expression (endogenous + transgenic) in cardiac OFTs
of Tgfb1 tg; Nfatc1-Cre Tg at E12.5. (A-F) Tgfb1 RNA scope ISH in cardiac OFTs
show increases in total Tgfb1 levels which is localized to the endocardium and
cushion mesenchymal cells in double transgenic embryos compared to
controls. (G) Images of E12.5 embryos show no gross morphological
abnormalities in the double transgenic mice
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Figure 2.27 Overexpression of Tgfb1 in endocardial cushion-derived VICs
causes double outlet right ventricle (DORV). (A) Cardiac muscle actin stain
shows DORV in the double transgenic mice in which both the aorta and
pulmonary artery open into the right ventricle with ventricular septal defect
(VSD) (B) AMIRA 3D reconstruction further confirms the DORV and VSD
phenotype in the double transgenic embryos (E13.5)
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Figure 2.28 Craniofacial malformations and aortic valve cartilage nodule
formation in Tgfb1Tg; Wnr1-Cre Tg embryos. (A) Images of E17.5 embryos
show severe craniofacial malformations (abnormal eyelid development, cleft lip
and unequal size cranial hemispheres) in double transgenic embryos (Tgfb1Tg;
Wnr1-Cre2 Tg) (B) H&E staining showing cartilage nodule in the aortic valve
hinge region of double transgenic embryos Tgfb1Tg; Wnr1-Cre1 Tg.
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Figure 2.29 Pharmacological reduction of Tgfb signaling attenuate CAVD
progression in 8 weeks Tgfb1Tg; Postn-Cre Tg mice. Treatment with Tgfb
receptor I inhibitor (SB431542) (treatment started at day 12 until 8 weeks
postnatally) reduces calcification area in double transgenic treated group
compared to vehicle control (N=6, 3 per group) (P-value= 0.096).
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Figure 2.30 Genetic reduction of Tgfb signaling attenuate CAVD
progression in 8 weeks Tgfb1Tg; Postn-Cre Tg mice. genetic
haploinsufficiency of Tgfb1 in the 8 weeks double transgenic mice reduces the
calcification area. P-value=0.337 (N=6, 3 per group).
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CHAPTER 3
CELL-TYPE SPECIFIC ROLE OF TRANSFORMING GROWTH
FACTOR BETA 2 (TGFβ2) IN CARDIAC OUTFLOW TRACT
MALFORMATIONS
3.1 INTRODUCTION
3.1.1 Outflow tract malformations:
Congenital heart defects (CHDs) are the most common types of birth
malformations and the leading cause of birth defect related deaths in children
(Gilboa, Salemi, Nembhard, Fixler, & Correa, 2010; Petrini, Damus, & Johnston,
1997). CHDs affects 9 per 1,000 live births worldwide or approximately 1.35 million
newborns annually (Dolk, Loane, Garne, & Group, 2011; van der Linde et al.,
2011). In the United State and according to a latest report, the estimated
prevalence of children and adults who lived with CHDs in 2010 was 2.4 million, in
whom 300 thousand had severe or critical CHDs (Gilboa et al., 2016). Besides the
morbidity and mortality associated with it, CHDs impose a substantial economic
burden with an estimated cost of hospitalization in the US exceeding more than $6
billion in 2013 (Arth et al., 2017). Outflow tract (OFT) (Figure 3.1) malformations
account for 30% of all CHDs (Neeb et al., 2013; Thom et al., 2006). OFT
development is a complex process that involves intricate cellular and molecular
interactions among myocardial, endocardial, and neural crest cell lineages (refer
to Chapter 1), which contribute to development of the mature sub-valvar left and
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right ventricular outlets, pulmonary and aortic roots, and intrapericardial arterial
trunks (Anderson et al., 2016). Defects in migration, EMT, proliferation, and
apoptosis of one or more of these cell lineages leads to impairment of endocardial
cushion formation, abnormal OFT septation and alignment, and defects in valve
development and remodeling (Lin et al., 2012; Neeb et al., 2013)
OFT malformations are the most severe forms of CHDs that require surgical
intervention during the first year of life (critical CHDs). They usually include more
than one abnormality such as: persistent truncus arteriosus (PTA), transposition
of great arteries (TGA), double outlet right ventricle (DORV), and overriding aorta
(OA) (Neeb et al., 2013; Zeng, Zhang, Liu, & Zhang, 2016). PTA accounts for 1%
of all CHDs and it occurs due to failure of development of the conotruncal septa
which result in single aortopulmonary root, single truncal valve with one to four
malformed thick leaflets, and ventricular septal defect (Butto, Lucas, & Edwards,
1986; A. Moorman et al., 2003; Reller, Strickland, Riehle-Colarusso, Mahle, &
Correa, 2008). PTA varies in location and is either connected predominantly to the
right ventricle, left ventricle, or centrally positioned over both ventricles (Butto et
al., 1986). TGA represent 5-7% of all CHDs and refers to reversed exits of the
atrial trunks in which the pulmonary and aortic arteries are connected to the left
and the right ventricles, respectively (Martins & Castela, 2008; Samánek et al.,
1989; Warnes, 2006). TGA can be categorized into TGA with normal
interventricular septa, TGA with VSD alone, or TGA with VSD and obstruction of
left ventricular OFT (Jaggers, Cameron, Herlong, & Ungerleider, 2000). TGA
occurs due to left-right asymmetry or it associates with defect in heart looping
85

during embryonic development (Desgrange, Le Garrec, & Meilhac, 2018). DORV
represents 1-1.5% of all CHDs and occurs when both the aorta and pulmonary
arteries are misaligned and connected to the right ventricle (Peixoto, Leal, Silva,
Moreira, & Ortiz, 1999). DORV can be classified into 4 types: DORV-committed
VSD type (associated with subaortic or subpulmonic VSD with no pulmonary
stenosis), DORV-Teratology of Fallot type (associated with committed VSD and
pulmonary stenosis), DORV-TGA type, and DORV-noncommitted VSD type
(associated with VSD near the ventricular inlet) (Walters et al., 2000). OA occurs
when the aortic valve is located over the muscular VSD as an isolated defect or
as a part of multiple heart defects, for example in association with teratology of
Fallot (right ventricular hypertrophy, pulmonary stenosis, VSD, and OA) which
accounts for 3.56% of all CHDs (Bailliard & Anderson, 2009; McCarthy, Ho, &
Anderson, 2000; Oppenheimer-Dekker et al., 1985; Samánek et al., 1989; Walters
et al., 2000). VSD is the most common type of congenital heart defect in children
(31.41% of all CHDs) and is characterized by a hole in the muscular or
perimembranous parts of the interventricular septum frequently accompanied the
outflow tract malformations (Samánek et al., 1989; Spicer, Hsu, Co-Vu, Anderson,
& Fricker, 2014). VSD varies in location and can be subaortic perimembranous
VSD, subpulmonic VSD, Muscular VSD, or atrioventricular inlet VSD (Spicer et al.,
2014; Walters et al., 2000).
Although environmental and genetic factors have been implicated in the
development of OFT malformations, for example: chromosomal abnormalities
(Down’s and Turner’s syndromes), smoking, viral infection (Rubella), maternal
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diabetes, and exposure to teratogens (Lithium Chloride), the underlying causes
and molecular dysregulations that lead to CHDs are not fully understood (Azhar &
Ware, 2016; Ul Haq et al., 2011).
3.1.2 Signs and symptoms, management, and outcomes of cardiac OFT
malformations:
Clinical presentations of OFT malformations range from mild asymptomatic
defects, e.g. bicuspid aortic valve (BAV) (Freeze, Landis, Ware, & Helm, 2016), to
sever defects manifested at birth e.g. PTA, TGA, and DORV (Zeng et al., 2016).
Patients with OFT malformations can present with cardiac and non-cardiac
manifestations, including: bluish discoloration of mucus membranes and skin
(cyanosis), abnormal heart sounds (murmur), tachycardia, tachypnea, bounding
pulse, growth restriction, poor feeding and/or signs of heart failure (Costello,
Gellatly, Daniel, Justo, & Weir, 2015; Dolbec & Mick, 2011; Sun, Liu, Lu, Zheng, &
Zhang, 2015).
OFT malformations can be diagnosed during pregnancy via prenatal
ultrasonography (using the outflow tract and the four-chamber views) and the fetal
echocardiogram (Bravo-Valenzuela, Peixoto, & Araujo Júnior, 2018; Olney, Ailes,
& Sontag, 2015). It can also be diagnosed postnatally using pulse oximetry
screening, electrocardiogram (ECG), and the echocardiogram to determine the
type of the defect, cardiac size, and heart function (heart rate, rhythm and
conduction activity) (Olney et al., 2015; Zeng et al., 2016).
To date, the main treatment option for OFT malformations is surgical
correction of the structural defects during the first year of life to restore the
unidirectional blood flow and preserve heart function (Zeng et al., 2016). Prognosis
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depends mainly on the type, time of diagnosis, and severity of the defect, and
because most of patients with OFT malformations are classified under critical
CHDs, they carry lower one-year survival rates (75.2%) compared to infants with
non-critical diseases (97.1%) (Oster et al., 2013).
3.1.4 Role of TGFβ2 in heart development and outflow tract malformations:
TGFβ2 is a pleiotropic growth factor expressed by the myocardium,
endocardium, epicardium and cushion mesenchyme cells during early heart
development (E9.5-E11.5), and it maintains its expression in the myocardium,
epicardium, and aortic wall throughout embryonic life (E12.5-E18.5) (Doetschman,
Barnett, et al., 2012; Molin et al., 2003). Tgfb2 regulates critical cellular events
during heart development including: formation and differentiation of EMT-derived
endocardial cushions, OFT septation and alignment, post-EMT valve remolding,
and the development of the aortic arch (Azhar et al., 2011; Azhar et al., 2009;
Azhar et al., 2003; Doetschman, Barnett, et al., 2012). Studies in humans have
shown a genetic link between Tgfb2 mutations and the development of congenital
heart defects in which TGFβ2 polymorphism is associated with the development
of outflow tract malformations (conotruncal defects) and ventricular septal defects,
while heterozygous loss of function mutations causes Loeys-Dietz syndrome
(LDS-type4) with dilatation and dissection of aortic root, bicuspid aortic valves, and
arterial tortuosity (Chen et al., 2017; Lindsay et al., 2012; Xie, Chen, Li, Zhou, &
Rao, 2012). Similarly, heterozygous loss of Tgfb2 causes dilation of the aortic root
in mice while the systemic ablation of Tgfb2 results in abnormal endocardial
cushion formation, PTA, DORV, valve thickening, and perinatal mortality (Azhar et
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al., 2011; Azhar et al., 2009; Bartram et al., 2001; Lindsay et al., 2012). However,
the systemic approach precludes the cell-type developmental effect of Tgfb2 in
OFT morphogenesis since multiple cell lineages produce and respond to the same
ligand in cell autonomous and non-autonomous fashions. The major challenge in
understanding the complex role of the TGFβ2 ligand in the pathogenesis of OFT
malformations is that TGFβ1 and SMAD signaling are significantly increased in
patients with Tgfb2 loss and cardiovascular malformations. This suggests that the
alternative ligand is overexpressed to compensate for Tgfb2 loss which may
actually drive the pathology of the disease (Lindsay et al., 2012; Schepers et al.,
2018).
Our previous finding showed that the TGFβ2 ligand, secreted by distinct
cardiac cell lineages, plays unique roles during cardiac OFT development. To
confirm and further extend these studies, here we will sort the autocrine-paracrine
roles of TGFβ2 produced by mesodermal, myocardial, endocardial, and neural
crest cell lineages in the OFT formation, septation and remodeling. Then we will
identify if Tgfb2 loss enhances Tgfb1 signaling which mediates OFT
malformations.
3.2 MATERIALS AND METHODS
3.2.1 Mice: All animal work was performed in accordance to protocols approved
by the Institutional Animal Care and Use Committee (IACUC) at the University of
South Carolina. The following mice were used in this study: Tgfb2flox/flox (Ishtiaq
Ahmed, Bose, Huang, & Azhar, 2014), Tgfb2+/- (Sanford et al., 1997), Tgfb2
TM1a+/1a (or Tgfb2+/Geo) (Ishtiaq Ahmed et al., 2014), Nkx2.5-CreTg (Stanley et al.,
2002), Wnt1-Cre1&2Tg (Danielian, Muccino, Rowitch, Michael, & McMahon, 1998;
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Lewis, Vasudevan, O'Neill, Soriano, & Bush, 2013), Tie2-CreTg (Kisanuki et al.,
2001), cTnT-CreTg (Jiao et al., 2003). Conditional Tgfb2 knockout embryos were
generated via two breeding steps (Figure 3.2). First, Nkx2.5-CreTg, Wnt1-Cre2Tg,
Tie2-CreTg, or cTnT-CreTg males were mated to Tgfb2+/- females to generate
Nkx2.5-CreTg; Tgfb2+/-, Wnt1-Cre1,2Tg; Tgfb2+/-, Tie2-CreTg; Tgfb2+/-, or cTnTCreTg Tgfb2+/- males, respectively. Second, the later males were mated to
Tgfb2flox/flox females to generate the following conditional knockout (CKO)
embryos: Tgfb2-mesodermal CKO (Tgfb2flox/+; Nkx2.5-CreTg; Tgfb2+/-), Tgfb2neural

crest

CKO

(Tgfb2flox/+;

Wnt1-Cre1&2Tg;

Tgfb2+/-),

Tgfb2-

enodthelial/endocardial CKO (Tgfb2flox/+; Tie2-CreTg; Tgfb2+/-), and Tgfb2myocardial CKO (Tgfb2flox/+; cTnT-CreTg; Tgfb2+/-). The Systemic knockout of
Tgfb2 was generated via breeding TM1a+/1a heterozygous males and females to
generate TM1a1a/1a embryos. Timed pregnancies were assessed via daily
monitoring of the presence of a mating plug at embryonic day E0.5. Then, at the
indicated time point, embryos were collected as follows: pregnant female mice
were scarified with Isoflurane inhalation, a transverse lower abdominal incision
was made in order to expose the uterine horns, embryos were released from the
uterine tissues and the surrounding yolk sac followed by thorough washing in
1xPBS. Tails were clipped and saved for genotyping (refer to appendix for the
primers sequences) and embryos were fixed in 4% paraformaldehyde for 24-48
hours. Embryo tissue processing was performed manually as follows: fixed tissues
were washed in 1xPBS, dehydrated in increasing concentrations of alcohol
(70%,95%,100%), cleared in xylene, and imbedded in paraffin. Serial sectioning
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was performed using a Leica microtome at 7um thickness starting from the level
of the aortic arch to include the entire heart.
3.2.2 Histological analysis: OFT morphological examination was performed
using H & E staining following a standard protocol as previously described (see
Chapter 2). Images of the serial sections were obtained using a Nikon E400 and
analyzed for the following: the presence of aortopulmonary septation, comparing
semilunar valve thickness and leaflet number of CKO to the littermate controls,
detection of an intraventricular septation defect, and analysis of the associated
malformations (e.g. atrioventricular valves defects and myocardial abnormalities).
Immunohistochemistry was performed using a DAKO LSAB universal kit as
follows: sections were deparaffinized in xylene (3 changes X 5 minutes),
rehydrated in a gradient of alcohol 100%, 95%, 70% (2 changes x 3 minutes) and
rinsed in distilled water (2 changes x 3 minutes). Heat induced antigen retrieval
was performed using 1x target antigen retrieval buffer for 30 minutes followed by
washing in distilled water (3 changes x 5 minutes) and an additional wash in
1xTBST (Tris-buffered saline in 0.1% Tween 20) for 3 minutes. Blocking of the
non-specific binding were performed using DAKO peroxidase block for
immunohistochemistry. Sections were incubated overnight at 4 deg C with the
following antibodies: Anti-pHistone3, Anti-cardiac muscle actin (HHf35), antiMF20. After washing with 1xPBST (3 changes x 5 minutes), sections were
incubated with Biotinylated link (contains the anti-mouse and anti-rabbit secondary
antibodies) for 30 minutes at room temperature. After washing in 1xTBST (3
changes x 5 minutes), sections were incubated in Streptavidin link for 30 minutes
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at room temperature. After washing in 1xTBST (3 changes x 5 minutes), signals
were detected using DAB chromogen. Apoptosis was detected using TUNEL ISH
following Promega manufacture’s protocol (FragEL™ DNA Fragmentation
Detection Kit) as previously described (refer to chapter 2). Tgfb1 and Tgfb2 RNA
scope ISH were performed following the manufacture’s (Advanced Cell
Diagnostic, Inc) protocol and probes (RNAscope Probe - Mm-Tgfb2-C2,
NAscope® Probe - Mm-Tgfb2, RNAscope Probe - Mm-Tgfb1) using RNA scope
2.5 HD BROWN Assay (cat# 322300) and RNA scope 2.5 HD Duplex Assay kits
3.2.3 Amira 3D reconstruction: serial sections of the whole embryonic heart for
wild-type embryos at E9.5 were imaged using the Nikon E400 microscope.
Similarly, serial sections of the entire aortic valve region of E16.5 controls and
Tgfb2flox/+; Nkx2-5-CreTg; Tgfb2+/- CKO embryos were imaged using a 4x
objective. Tiff images were loaded into the Amira software and aligned manually.
Segmentation was performed using the Lasso tool or the magic wand tools to
manually trace the boundaries of the aortic valve leaflets or the heart and the
endocardial cushions on each section followed by a reconstruction of the 3D
image. The surface of each 3D module was smoothed, and the images were saved
and exported as Tiff files.
3.2.4 Real-Time qPCR: Cardiac outflow tracts of E12.5 Tm1a knockout embryos
and littermate wildtypes were micro-dissected and saved in RNA later solution at
-20 C. RNA extraction and purification were performed using miRNeasy Mini Kit
following the manufacture’s recommended protocols. RNA is reverse transcribed
into cDNA using Bio-Rad iScript Reverse Transcription Supermix for RT-qPCR.
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Real time qPCR was performed using the following PrimePCR™ SYBR® Green
Assays (Bio-Rad Laboratories: Tgfb1 (UniqueAssayID: qMmuCED0044726),
Tgfb2

(UniqueAssayID:

qMmuCID0024408)

Tgfb3

(UniqueAssayID:

qMmuCED0045203), Gapdh (UniqueAssayID: qMmuCED0027497). Relative
gene expression was estimated using the delta delta Ct (∆∆Ct) method after
normalizing to Gapdh internal reference control.
3.2.5 Western blotting: Cardiac outflow tracts of E12.5 Tgfb1 tg; Nfatc1-Cre

Tg

embryos and the littermate wildtype controls were micro-dissected and lysed in
1xRIPA

(radioimmunoprecipitation

assay)

buffer

supplemented

with

phenylmethylsulphonyl fluoride (PMSF) protease inhibitor for 2 hours on ice
followed by centrifugation at 12000 g for 30 minutes at 4 deg C. Protein
concentration was estimated using a Thermofisher BCA kit according to the
manufacturer’s protocol. Protein samples were mixed with SDS loading dye and
denatured by boiling at 100 deg C for 5 minutes. Equal amounts of protein samples
were loaded on Invitrogen gradient acrylamide gels and resolved by
electrophoresis. Proteins were transferred to a PVDV membrane using an
Invitrogen iBlot Dry Blotting System. After washing in 1xPBST, membranes were
blocked in 5% BSA in TBST for 6 hours followed by incubation with primary
antibodies (phospho-Smad2/3, Smad2/3, phospho- Smad 1,5, Smad1,5, phosphop38, p38, and β-actin) and diluted 1:1000 in blocking buffer overnight at 4 deg C.
After washing in 1xPBST, membranes were incubated with HRP-labeled antirabbit
or anti mouse secondary antibody diluted in blocking buffer (1:5000). Detections
were performed using Bio-Rad Clarity Western ECL substrate and X-Ray film.
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3.2.6 Statistical analysis: Statistical analysis for comparisons between two
groups was performed using unpaired Student t-test. One-tailed P-values of 0.05
were considered significant. Error-bars represent the standard deviations (SD) for
the groups. GraphPad InStat was used to perform all statistical analysis
(www.graphpad.com).
3.3 RESULTS
3.3.1 Conditional ablation of Tgfb2 from mouse neural crest cell lineage
leads to aortic valve thickening and perimembranous VSD.
To understand the role of the neural crest-produced Tgfb2 in cardiac outflow
development and septation, we generated Tgfb2+/+, Wnt1-Cre1Tg; Tgfb2+/- and
Tgfb2+/flox, Wnt1-Cre2Tg; Tgfb2+/- conditional knockout (CKO) embryos and
littermate controls. Morphological examination of E13.5-E17.5 embryos showed
no gross malformations or changes in CKO size compared to the littermate
controls (Figure 3.3). H&E staining of serial sections of embryonic hearts and
arterial trunks showed well-developed aortopulmonary septa in both CKO and
littermate controls (Figure 3.4). On other hand, histological analysis of the heart
valves revealed marked thickening of the aortic and pulmonary valves in 75% of
cases compared to controls (Figure 3.4 and 3.5). No obvious changes in the mitral
and tricuspid valve thicknesses were observed in the conditional knockouts relative
to the controls (Figure 3.6). Perimembranous (type2) VSDs were observed in 25%
of CKOs compared to normal interventricular septa formation in the controls. Table
3.1 summarized the cardiovascular malformations in response to mouse neural
crest deletion of Tgfb2.
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3.3.2 Deletion of Tgfb2 in mouse cardiac mesodermal cell lineages causes
bicuspid aortic valve, cardiac valve thickening, and smaller right ventricles.
We next reconfirmed and extended previous finding to determine the
function of Tgfb2-produced by mesodermal cell lineages in mouse outflow tract
malformations. We developed Tgfb2+/flox+; Nkx2-5-CreTg; Tgfb2+/- conditional
knockouts (CKO) embryos (E13.5-E17.5). Gross examination showed a mild
reduction in apparently normal CKO embryos compared to their littermate controls
(Figure 3.7). Histological analysis of embryonic hearts and the pulmonary and
arterial trunks revealed multiple congenital heart defects in the conditional
knockouts compared to controls (Table 3.2).

Pulmonary and aortic valve

thickening were observed in 60% of the conditional knockouts compared to the
controls (Figure 3.8). Bicuspid aortic valve was observed in 60% of the conditional
knockout embryos with either fusion of the left and right leaflets or the left and noncoronary leaflets compared to three well-developed leaflets in the littermate
controls (Figure 3.9 and 3.10). Perimembranous and atrioventricular septal defects
were evident in 60% of conditional knockouts compared to proper ventricular
septation in the littermate controls (Figure 3.11). Mitral and tricuspid valves were
also markedly thicker in 60% of conditional knockouts relative to controls (Figure
3.12) while 20% developed small and thick right ventricle compared to controls
(Figure 3.13).
3.3.3 Knockout of myocardial-produced Tgfb2 leads to aortic valve
thickening, perimembranous and muscular VSDs, and thinning of right
ventricular myocardium.
Nkx2.5Cre mice effectively deleted Tgfb2 in the myocardium and revealed
important role of myocardial TGFβ2 in heart development. However, Nkx2.5Cre
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mice can delete Tgfb2 in non-myocardial cell lineages. Consequently, to test the
role of exclusively myocardial produced Tgfb2 on OFT development, we generated
Tgfb2+/flox; cTnT-CreTg; Tgfb2+/- embryos. No gross morphological abnormalities
were detected in CKOs while a slight reduction in body size were observed in
CKOs compared to controls (Figure 3.14). Histological analysis showed normal
aortopulmonary septation in CKOs, however, 60% of cases had severe aortic valve
thickening compared to littermate controls (Figure 3.15). In addition, 80% of CKOs
developed

various

types

of

interventricular

septal

defects

including

perimembranous, atrioventricular, and muscular VSDs (Figure 3.16). Furthermore,
60% of CKOs had myocardial thinning of the right ventricle which particularly
involved the compact myocardium with prominent elongated trabecula (myocardial
non-compaction) (Figure 3.17). TUNEL analysis shows reduction of OFT
apoptosis compared to control, while Phospho-HistoneH3 immunohistochemistry
showed reduction in myocardial cell proliferation of the right ventricle and
ventricular septa compared to control (Figure 3.18). Summary of the cardiac
malformations in response to myocardial deletion of Tgfb2 are summarized in
Table 3.3.
3.3.4 Conditional deletion of Tgfb2 in endocardial cell lineages causes
growth retardation, OFT septation and alignment defects, marked valve
thickening, and membranous and perimembranous VSD.
We next confirmed and extended previous findings to determine the role of
endocardial-produced Tgfb2 in OFT septation, alignment, and remodeling using
Tie2-Cre mice. We generated Tgfb2+/flox; Tie2-CreTg; Tgfb2+/- embryos and
littermate controls. Morphological examination showed that CKOs were markedly
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smaller in size than their littermate controls at all ages (Figure 3.19). Histological
analysis of serial sections of E13.5-E18.5 CKOs and their littermate controls show
that 87.5% of CKOs have OFT malformations and/ or remodeling defects Table
3.4. serial sections from the level of the aortic arch to the level of ventricular outlets
showed that 25% of CKOs had PTA (Figures 3.20 & 3.21) with 75% of CKOs
having marked aortic and pulmonary valve thickening (Figure 3.22, and 3.23).
Further examination of the ventricular septa showed that 50% of CKOs developed
VSDs (perimembranous and atrioventricular septal defect with overriding tricuspid
valve) (Figure 3.24). Endocardial deletion of Tgfb2 also resulted in atrioventricular
remodeling defects with 50% of CKOs having massive mitral and tricuspid valve
thickening compared to littermate controls (Figure 3.25).
3.3.5 Systemic deletion Tgfb2 causes paradoxical increases in alternate Tgfb
ligand gene expression:
Further studies were conducted to test the effects of Tgfb2 Knockout on
gene expression of Tgfb1,2,3 ligands during outflow tract development. Relative
gene expressions were measured via real time qPCR performed on RNA samples
obtained from cardiac OFT tissues of E12.5 knockouts embryos (N=3) and
littermate controls (N=5). The preliminary results confirmed what in the Tgfb2
knockouts and showed marked reduction of Tgfb2 gene expression. In contrast,
Tgfb1 and Tgfb3 gene transcripts were both upregulated in response to Tgfb2 loss
(Figure 3.26).
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3.3.6 Overexpression of Tgfb1 in endocardial cell lineage causes DORV, a
paradoxical decrease in OFT Tgfb2 expression, activation of canonical and
non-canonical Tgfb pathways, and suppression of BMP canonical pathway:
Finally, we confirmed and tested the casual link between augmented Tgfb1
signaling and OFT malformations, and we conditionally overexpressed Tgfb1 in
endocardial cell lineage using Nfatc1-Cre mice (Refer to Chapter 2). Our results
confirmed that double transgenic mice developed severe OFT malformations
(double outlet right ventricle with overriding aorta). Furthermore, ISH confirmed the
paradoxical relationship between Tgfb1 and Tgfb2, where Tgfb2 is reduced in
response to Tgfb1 overexpression during OFT development (Figure 3.27). We also
tested the potential pathways by which Tgfb1 disrupted OFT malformations. Our
results show increases in both activated SMAD2 canonical and activated P38 noncanonical pathway and drastic inhibition of BMP canonical pathway (SMAD1/5/8),
a parallel pathway important for endocardial cushion formation and OFT
morphogenesis (Figure 3.30).
3.4 DISCUSSION
Clinical studies and systemic knockout of Tgfb2 in mice have been
associated with severe OFT malformations (Bartram et al., 2001; Lindsay et al.,
2012), however, the cell lineage-specific role of Tgfb2 in OFT development
remains unknown. In the present study we developed, for the first time, Tgfb2
conditional knockout mice to investigate the role of neural crest, mesodermal,
myocardial, and endocardial- produced Tgfb2 in OFT formation and remolding. We
found that Tgfb2 deletion in different cell types disrupts OFT septation and/or
remodeling and causes distinct and overlapping cardiovascular malformations.
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Cardiac neural crest cells (CNCs) are migratory multipotent cells that
originate from the vagal neural crest and migrate to the developing heart around
E10.5 (Hutchins et al., 2018; Hutson & Kirby, 2003; Kirby, Gale, & Stewart, 1983).
CNCs contribute to distal OFT cushion formation and aortopulmonary septation,
regulate the addition of the second heart field-derived myocardial cells to the
arterial pole during heart development (Hutchins et al., 2018; Hutson & Kirby,
2003; Kirby et al., 1983). Genetic deletion of CNCs results in aortopulmonary
septation defects (e.g. PTA), OFT alignment defect (e.g. OA and DORV), and great
artery remodeling defects (e.g. interrupted or double aortic arch)(Hutson & Kirby,
2003). Tgfb2 is a critical cue for neural crest-mediated aortopulmonary septations
and OFT alignment and the systemic knockout of Tgfb2 in mice results in PTA,
DORV, aortic arch malformations, and marked semilunar valves thickening (Azhar
et al., 2011; Bartram et al., 2001). Similarly, ablation of Tgfb receptor I&II in neural
crest cells causes PTA and interrupted aortic arch (Choudhary et al., 2006; J.
Wang et al., 2006; Wurdak et al., 2005). To test whether neural crest produced
Tgfb2 is required for OFT septation and alignment, we generated Tgfb2-neural
crest conditional knockout embryos using Wnt1Cre1 and 2 mouse lines, which
express the Cre recombinase under control of the Wnt1 promotor of neural crest
cells. Interestingly and opposite to what we expected, our results showed a welldeveloped aortopulmonary septa and mild thickening of semilunar valves, in
contrast to previous studies where conditional deletion of Tgfb receptors in mouse
neural crest cells causes OFT septation defect. These results suggest that neural
crest produced Tgfb2 is not required for OFT septation and alignment, however, it
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is required for post-EMT semilunar valve remodeling. Our results also suggest that
paracrine Tgfb2 signaling produced by mesodermal cell lineage (endocardial
and/or myocardial cells) act in paracrine manner to regulate neural crest-mediated
OFT septation.
We next deleted Tgfb2 from mesodermal cell lineages via Nkx2-5-Cre in
which the Cre recombinase is under control of the Nkx2-5 promoter and mediates
Tgfb2 deletion in the cardiac crescent, the myocardium, and part of the
endocardium (mosaic or patchy expression)(Stanley et al., 2002). Mesodermal
Tgfb2 deletion resulted in more severe OFT development and remodeling defects
including: Bicuspid aortic valve, ventricular septation defects, and formation of
small hypertrophic right ventricle while apparently normal left ventricle
development. These results imply that Tgfb2 has a significant effect on the
development of the second heart field derived structures (OFT and the right
ventricle) which require further investigation via conditional deletion of Tgfb2 in the
second heart filed using Mef2c-Cre mice.
Since the recombinase activity of Nkx2.5-Cre mice is detected in both the
myocardium and to lesser extent in the endocardium of the developing cardiac
outflow tract, we generated specific Tgfb2 conditional knockout embryos to test the
cell-type specific role of Tgfb2 in either the myocardium or endocardium using
cTnT-Cre and Tie2-Cre, respectively.
Tgfb2 is highly expressed by the myocardium of the OFT and ventricles
throughout heart development, suggesting its critical role in OFT and chamber
morphogenesis (Doetschman, Barnett, et al., 2012; Molin et al., 2003). To further
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understand the role of myocardial produced Tgfb2 in OFT development, we
deleted Tgfb2 from myocardial cell lineages using the cTnT-Cre mouse line, which
express the Cre-recombinase in the early cardiomyocytes. Our results indicated
that OFT formation and septation were independent on myocardial produced
Tgfb2, however, myocardial produced Tgfb2 was essential for remodeling of aortic
valves and the development of the right ventricle. We further tested the effect of
myocardial deletion on two vital physiological process, apoptosis, which plays
significant roles in OFT endocardial cushion remodeling, and proliferation, which
regulate ventricular expansion, trabeculae formation, and myocardial growth and
compaction to establish a mature ventricular wall (Evans, Yelon, Conlon, & Kirby,
2010; Webb, Qayyum, Anderson, Lamers, & Richardson, 2003). Our results
indicate that both processes were dysregulated in CKO embryos compared to
controls which could explain in part the cellular events underlying the congenital
heart defects in response to myocardial Tgfb2 loss. These results further confirmed
the significant role of Tgfb2 in the development of the second heart field derived
OFT and right ventricular myocardium that requires further investigation.
Next, we deleted Tgfb2 from endocardial cell lineages using the Tie2-Cre
transgenic mouse line, which expresses the Cre recombinase under control of the
Tie2 promotor and mediates Tgfb2 deletion in the endothelium, endocardium and
the proximal OFT cushion’s mesenchymal cells (excluding the distal OFT cushion
mesenchyme) (Kisanuki et al., 2001). Interestingly, our results show that loss of
endocardial produced Tgfb2 had detrimental effects on OFT development and
remodeling as reflected by failure of aortopulmonary septation (PTA), post-EMT
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valve remodeling defects, defective ventricular septation (VSD), and severe
intrauterine growth restriction. These results indicate a novel finding that
endocardial-produced Tgfb2 acts in a paracrine fashion to regulate the migration,
colonization and/or differentiation of cardiac neural crest cells and proper outflow
tract septation which requires further investigation.
VSD was a common phenotype among all types of Tgfb2 conditional
knockouts either as an isolated defect or in combination with other malformations.
This may be attributed to the complex origin of ventricular septa which require
intricate communication with and contributions from myocardial, endocardial and
neural crest cell lineages during early heart development (Gao et al., 2010; Lin et
al., 2012). Tgfb2 loss leads to OFT alignment and septation defects which can
interfere with proper development of interventricular septa during early heart
development and result in VSD (Lin, 2016).
Additionally, our results showed that embryos with identical conditional
genetic ablation of Tgfb2 (littermates CKOs) developed various phenotypes. The
difference in phenotypic penetrance in response to Tgfb2 mutations implies that
embryos with no or mild phenotype may compensate for the Tgfb2 loss via different
or more robust molecular mechanisms. On the other hand, the variations in
phenotypes may reflect the difference in the efficiency or the level of the Cre
transgene among conditional knockouts embryos, which can be further validated
via integrating reporter mice to the Tgfb2 Cre-LoxP system (Klinger, Chmura, &
Killeen, 2010).
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Although the present work provided a comprehensive analysis of post EMT
(E13.5-E18.5) cell-type specific roles of Tgfb2 in OFT development, further lineage
tracing studies and histological analysis (e.g. cell proliferation, apoptosis, EMT,
extracellular matrix production, cell fate mapping, and differentiation) during
endocardial cushion formation and OFT septation (E9.5-E12.5) are required to
understand the underlying cellular and molecular mechanisms that govern OFT
malformations in response to Tgfb2 loss.
Another big dilemma in understanding the complex role of Tgfb signaling in
OFT development is the presence of paradoxical hyperactivation of Tgfb1
signaling in LDS patients whose primary defect is Tgfb2 loss of function mutations
(Lindsay et al., 2012). Tgfb1 has some overlapping expression with Tgfb2 during
heart development, and our preliminary results showed increased in Tgfb1 gene
expression in cardiac outflow tracts in response to Tgfb2 systemic knockouts. To
establish a direct cause-effect relationship between the Tgfb2 loss and the
increased Tgfb1 signaling in development of OFT malformations, we generated
Tgfb1; Nfatc1-Cre embryos which characterized by increased bioactive Tgfb1
expression in the endocardial cell lineages (refer to chapter 2). Our results indicate
that Tgfb1 hyperactivation leads to cardiac alignment and septation defects
(DORV, OA, and VSD) (Chapter 2) with increased Tgfb1 canonical and noncanonical signaling.
We further tested the mechanisms by which Tgfb1 overexpression causes
OFT

malformations

using

immunoblotting

for

BMP

canonical

signaling

(SMAD1,5,9). Bone morphogenic protein BMP is another member of the Tgfb
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superfamily which is expressed by the myocardium and to lesser extent by the
endocardium (W. Liu et al., 2004; Ma, Lu, Schwartz, & Martin, 2005; McCulley,
Kang, Martin, & Black, 2008). Defective BMP singling results in abnormal
endocardial cushion formation and defective outflow tract septation (W. Liu et al.,
2004; Ma et al., 2005; McCulley et al., 2008). Our results showed that Tgfb1
drastically inhibits Smad1,5 which require further confirmation using Bmp
response element (BRE)-lacZ reporter mice (Monteiro, de Sousa Lopes,
Korchynskyi, ten Dijke, & Mummery, 2004) to identify a potential link between the
two genes during OFT development.
In summary, this study provides for the first time a novel paracrine
mechanism by which endocardial produced Tgfb2 regulates OFT septation and
alignment and suggests that the increase in Tgfb1 signaling (both the canonical
and non-canonical pathways) was sufficient to drive the development and
progression of OFT malformations in vivo.
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Figure 3.1 The outflow tract (OFT) of E9.5 embryonic heart: (A) Image of
mouse embryonic heart E9.5(B) Amira 3D reconstruction of E9.5 heart showing
the OFT located at the arterial pole and connected to the primitive ventricle.
Red, yellow, green segmentations indicate the myocardium, outflow tract
cushions, and atrioventricular cushions, respectively

.
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Figure 3.2 Schematic of Tgfb2 conditional knockout (CKO) mice breeding:
(A) Tgfb2-neural crest CKO, (B) Tgfb2-Mesodermal CKO, (C) Tgfb2Myocardial CKO (D) Tgfb2- Endocardial CKO (E) Tgfb2 Flox-Cre CKO strategy.
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Figure 3.3 No gross morphological abnormalities of Tgfb2+/flox; Wnt1Cre2Tg; Tgfb2+/- embryo compared to littermate control (E16.5): (A) Image
of wildtype control embryo (B) Image of Tgfb2- neural crest conditional knockout
embryo
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AoV

Figure 3.4 Aortic valve thickening of Tgfb2+/flox; Wnt1-CreTg; Tgfb2+/embryo compared to littermate control (E13.5-E16.5): (A-D) MF-20
immunohistochemistry and H&E staining show aortic valve remodeling defect
and thickening of Tgfb2+/flox; Wnt1-Cre1Tg; Tgfb2+/- conditional knockout
embryos compared to wildtype controls (E-F) Similarly, H&E staining show
aortic valve thickening (E16.5) of Tgfb2+/flox; Wnt1-Cre2Tg; Tgfb2+/- conditional
knockout compared to wildtype control
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Figure 3.5 Mild thickening of pulmonary valve in Tgfb2+/flox; Wnt1-Cre1Tg;
Tgfb2+/- embryo compared to littermate control (E16.5): (A) H&E staining of
the pulmonary valve of wildtype control embryo (B) H&E staining shows mild
pulmonary valve thickening of the neural crest-Tgfb2 conditional knockout
embryo
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Figure 3.6 No marked changes in mitral or tricuspid valve thickness in
Tgfb2+/flox; Wnt1-Cre1Tg; Tgfb2+/- embryo compared to littermate control
(E16.5): (A) H&E staining of the mitral and tricuspid valve of wildtype control (B)
H&E staining shows no obvious difference in mitral and tricuspid valve
thickening of neural crest Tgfb2 conditional knockout embryo compared to
control
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Figure 3.7 No gross morphological abnormalities of Tgfb2+/flox; Nkx2-5CreTg; Tgfb2+/- embryo compared to littermate control (E16.5): (A) Image of
wildtype control (B) Image of Tgfb2- mesodermal conditional knockout show
mild reduction in the embryo size compared to control
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Figure 3.8 Aortic and pulmonary valve thickening of Tgfb2+/flox; Nkx2-5CreTg; Tgfb2+/- embryo compared to littermate control (E17.5): (A-B) H&E
staining show aortic valve thickening of Tgfb2-mesodermal conditional
knockout compared to wildtype control (C-D) H&E staining show pulmonary
valve thickening of Tgfb2-mesodermal conditional knockout compared to
wildtype control
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Figure 3.9 BAV development in Tgfb2+/flox; Nkx2-5-CreTg; Tgfb2+/- embryo
compared to littermate control (E13.5): (A, B) cardiac muscle actin and H &
E shows fusion of the left and right leaflets (BAV) in the CKO compared to welldeveloped tri-leaflets in the wild type control. (C&D) cardiac muscle actin and H
& E shows fusion of the left and non-coronary (BAV) in the CKO compared to
well-developed tri-leaflets in the wild type control
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Figure 3.10 Early fusion of aortic valve leaflets (Bicuspid aortic valve) in
Tgfb2+/flox; Nkx2-5-CreTg; Tgfb2+/- embryo compared to littermate control
(E13.5): (A and B) cardiac muscle actin IHC staining show normal tri-leaflet
aortic valves in the wildtype control (C and D) Amira 3 reconstruction show
fusion of left and non-coronary leaflets (BAV) with third rudimentary leaflet in
the CKO embryos compared to controls (BAV)
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Figure 3.11 Atrioventricular and perimembranous VSDs in Tgfb2+/flox;
NKX2-5-CreTg; Tgfb2+/- embryos compared to littermate control (E13.5E17.5): (A, B) H&E staining shows normal septations of heart chambers in the
wild type control, while atrioventricular VSD developed in the CKO.(C&B) H&E
staining of Tgfb2 mesodermal conditional knockouts show perimembranous
VSD compared to normal ventricular septation in the littermate control
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Figure 3.12 Tricuspid and mitral valve thickening of Tgfb2+/flox; Nkx2-5CreTg; Tgfb2+/- embryo compared to littermate control (E13.5-E17.5): (A-B)
H&E staining shows tricuspid and mitral valve remodeling defects of Tgfb2mesodermal conditional knockout compared to wildtype control (C-D) H&E
staining show marked tricuspid and mitral valves thickening of Tgfb2mesodermal conditional knockout compared to wildtype control
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Figure 3.13 abnormal development of the right ventricle in Tgfb2+/flox;
NKX2-5-CreTg; Tgfb2+/- embryo compared to littermate control (E13.5E17.5): (A, B) H&E staining show maldevelopment of the right ventricle in CKO
compared to control(C&D) H&E staining show severely underdeveloped right
ventricle with marked thickening of the right ventricular myocardium
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Figure 3.14 No gross morphological abnormalities of Tgfb2+/flox; cTnTCreTg; Tgfb2+/- embryos compared to littermate controls (E9.5-E13.5): (A,
C) Images of wild type controls embryos (B&D) Images of CKOs show mild
reduction in the size of otherwise normal looking embryo
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Figure 3.15 Aortic valve thickening and remodeling defects of Tgfb2+/flox;
cTnT-CreTg; Tgfb2+/- embryo compared to littermate control (E13.5): (A&C)
MF20 Immunohistochemistry show normal aortic valve of the wildtype control
(B&D) and severe aortic valve thickening and stenosis of Tgfb2- myocardial
conditional knockout
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Figure 3.16 Ventricular septal defects and thinning of the right ventricular
myocardium of Tgfb2+/flox; cTnT-CreTg; Tgfb2+/- embryos compared to
littermate controls (E13.5-E16.5): (A, C, &E) H&E (E13.5) and MF20
immunohistochemistry show well developed interventricular septa in the wild
type controls. (B, D, & F) H&E and MF20 immunohistochemistry (E16.5) of the
myocardial conditional knockout’s embryos show atrioventricular septal defects
in B, muscular septal defect in D and perimembranous septal defect in F
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Figure 3.17 Intrauterine growth restriction of Tgfb2+/flox; Tie2-CreTg;
Tgfb2+/- embryo compared to littermate controls (E16.5-E17.5): (A&C)
Images of normal size wildtype embryos (B&D) images of Tgfb2 endocardial
conditional knockouts show severe reduction in overall size of CKO embryos
compared to littermate controls
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Figure 3.18 Persistent truncus arteriosus with fusion of right and left
ventricular outlets in Tgfb2+/flox; Tie2-CreTg; Tgfb2+/- embryo compared to
littermate controls (E17.5): (A,C,E) H&E staining shows normal septation of
pulmonary and aortic trunks with normal opening into the right or left ventricle,
respectively (B,D&F) H&E staining of Tgfb2-endocardial conditional knockouts
shows defective aortopulmonary septation in which the pulmonary and aortic
trunks are fused near the ventricular outlets & share a common truncal valve
and both open into the right ventricles
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Figure 3.19 Persistent truncus arteriosus with fusion of right and left
ventricular outlets and the aortic and pulmonary trunks in Tgfb2+/flox; Tie2CreTg; Tgfb2+/- embryo compared to littermate controls (E17.5): (A,C,E)
H&E staining show normal septations of pulmonary and aortic trunks with
normal openings into the right or left ventricle, respectively. (B, D&F) H&E
staining of Tgfb2 endocardial conditional knockouts show complete fusion of
the aortic and pulmonary trunks which share a common truncal valve and both
open into the right ventricle
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Figure 3.20 Severe thickening of pulmonary valve in Tgfb2+/flox; Tie2-CreTg;
Tgfb2+/- embryos compared to littermate controls (E13.5-E17.5): (A-E)
Image of wildtype controls (B) Image of Tgfb2- endocardial conditional
knockouts with marked pulmonary valve thickening.
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Figure 3.21 Severe thickening of aortic valves in Tgfb2+/flox; Tie2-CreTg;
Tgfb2+/- embryos compared to littermate controls (E13.5-E16.5): (A, C, E)
Images of wildtype control (B, D, &F) Images of Tgfb2- endocardial conditional
knockouts with marked aortic valve thickening
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Figure 3.22 Ventricular septal defects of Tgfb2+/flox; Tie2-CreTg; Tgfb2+/embryos compared to littermate controls (E16.5-E17.5): (A, C, E) H&E
(E13.5, E16.5, E17.5) show normal interventricular septa in the wildtype
controls. (B, D, F) H&E staining of the endocardial conditional knockout
embryos show subaortic, perimembranous, and atrioventricular septal defect,
respectively

126

A

B

C

D

Figure 3.23 Severe tricuspid and mitral valve thickening of Tgfb2+/flox; Tie2-CreTg; Tgfb2+/- embryos compared to littermate controls (E16.5-E17.5):
(A,C) H&E staining show normal tricuspid and mitral valve of wildtype controls
(B,D) sever thickening of the mitral and tricuspid valves in the CKOs compared
to controls
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Figure 3.24 Tgfb1 and Tgfb2 RNA Scope ISH expression in OFT of Tgfb1,
Nfatc1-cre and littermate control: (A, B) Increased Tgfb1 in double transgenic
compared to control (E12.5) (N=4, 2 control and 2 DTG) (C, D) Reduced Tgfb2
expression in OFT of double transgenic compared to control (N=4, 2 controls
and 2 dtg)
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Figure 3.25 Increased Tgfb1 and Tgfb3 relative gene expression in
Tm1a1a/1a embryos compared to littermate controls (E12.5): qPCR of
cardiac OFT confirmed the Tgfb2 knockout in Tm1a1a/1a and showed
paradoxical increase in Tgfb1 and Tgfb3 genes expression of Tm1a1a/1a
knockouts relative to controls (P-Value= 0.472, 0.058, 0.570 for Tgfb1, Tgfb2,
Tgfb3, respectively). (N=3 knockouts, 5 wild types controls)
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Figure 3.26 Activation of canonical and non-canonical pathways in
cardiac OFT of Tgfb1, Nfatc1- cre with downregulation of Bmp canonical
signaling compared to controls (E12.5): (A) western blot of pSmad2 and
Smad2 (canonical pathway) show increased phosphorylation in the double
transgenics compared to controls (B) western blot of pp38 and p38 (noncanonical pathway) show increased phosphorylation in the double transgenics
compared to controls (C) western blot of pSmad1,5 and Smad1,5 (BMP
canonical pathway) show complete inhibition of
phosphorylation and
expression of the total protein in the double transgenic compared to control
(N=4,2 ctrl and 2 DTG)
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CHAPTER 4
GLOBAL DELETION OF TRANSFORMING GROWTH FACTOR
BETA 3 (TGFβ3) LEADS TO OUTFLOW TRACT
MALFORMATIONS AND MYOCARDIAL DEFECTS
4.1 INTRODUCTION
4.1.1: Expression pattern of Tgfb3 in embryonic and adult hearts:
Among the three Tgfb ligands, Tgfb3 is the last to be expressed within the
growing heart during mouse embryonic development (Doetschman, Barnett, et al.,
2012; Molin et al., 2003). Initially, Tgfb3 can be detected in cushion mesenchymal
cells around E12.5 of cardiac morphogenesis (Molin et al., 2003). Subsequently,
steady increases in Tgfb3 expression can be observed in the cardiac fibrous
skeleton and atrial septum primum between E14.5-E18.5 of post-EMT heart
development (Molin et al., 2003). In the adult heart, expression of Tgfb3 has not
been found in mice (Doetschman, Barnett, et al., 2012), however, TGFβ3 is
detected in the human adult myocardium in healthy and diseased conditions (Qu
et al., 2016; Rampazzo et al., 2003).
4.1.2: TGFβ3 mutation and Human Arrhythmogenic Right Ventricular
Dysplasia (ARVD):
ARVD is a genetic disease of the myocardium characterized by progressive
degeneration and thinning of the right ventricular myocardium (cardiomyopathy)
which is replaced by fatty-fibrous tissue (Basso, Corrado, Marcus, Nava, & Thiene,
2009; Marcus et al., 1982; Pilichou et al., 2016). AVRD affects 1:1000 - 1:5000 of
131

the population and manifests as arrythmia, cardiomegaly, heart failure and/or
sudden death in young adults, especially in athletics, with males affected more
often than females and the average age of presentation is around 26 years (Basso
et al., 2009; Corrado & Thiene, 2006; Dalal et al., 2005; James et al., 2013; Marcus
et al., 1982; Raman, Basso, Tandri, & Taylor, 2010). Pathologically, ARVD is
characterized by myocyte degeneration and apoptosis which involves a critical
area of the right ventricular myocardium called “the triangle of dysplasia” that
includes the right ventricular outflow tract and the free wall of the right ventricle
(the apex and the base)(Raman et al., 2010). To date, there is no cure for AVRD
and management depends mainly on early screening for the disease, exercise
restriction, catheter ablation, implantable cardioverter defibrillator, antiarrhythmics
drugs, and/or cardiac transplant (Corrado et al., 2015).
Mutations in the desmosomal or non-desmosomal genes have been
reported in AVRD patients (Beffagna et al., 2005; Pilichou et al., 2016). TGFβ3 is
an important regulator of cell differentiation, EMT, muscle development, and ECM
production (Kaartinen et al., 1995; Massagué, 2012; Rienhoff et al., 2013). Genetic
analysis has shown a strong association between TGFβ3 mutations and AVRD
type1(autosomal dominant disorder). Patients with ARVD have a substitution of
the nucleotides in the untranslated regions of the TGFβ3 gene, while no mutations
have been identified in the exon regions (Beffagna et al., 2005; Pilichou et al.,
2016; Rampazzo et al., 2003).
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4.1.3 TGFβ3 mutations and syndromic human aortic aneurysms and
dissection
Aortic aneurysm is one of the leading causes of illness and death in the
United States which is characterized by localized weakness and dilation in the
aortic wall (Caglayan & Dundar, 2009; Lilienfeld, Gunderson, Sprafka, & Vargas,
1987).

Severe aortic root aneurysms have been discovered in patients with

connective tissue disorders, for example Loeys-Dietz syndrome and Marfan
syndrome, which carry a high risk of death due to early aortic dissection and
rupture in asymptomatic young adults which requires early surgical correction
(Bertoli-Avella et al., 2015; Lacro et al., 2013; MacFarlane et al., 2019).
Recent studies identified TGFβ3 genetic mutation as the underlying cause
of LDS patients type 5 which is characterized by multiple connective tissues
abnormalities including syndromic aortic aneurysm and dissection (Bertoli-Avella
et al., 2015). Wide genome linkage and sequencing analysis by Bertoli-Avella et
al. shows that families with syndromic aortic aneurysms harbor several mutations
in the TGFβ3 gene which are critical to the function of the mature peptide including:
truncating mutations, in-frame splice site mutations of the TGFβ3 domain, and
missense mutations of the LAP domain (Bertoli-Avella et al., 2015). These studies
provide comprehensive analysis of the genetic basis of TGFβ3 loss of function
mutations that have been linked to human cardiovascular malformations, yet, the
underlying mechanism is poorly understood.
Although Tgfb3 is strongly expressed during the post EMT phase of heart
development, there is little known about its role in OFT and myocardial remodeling.
Our previous finding showed that systemic Tgfb3 knockout embryos and fetuses
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develop cardiac malformations. To confirm and further extend these studies, here
we hypothesize that Tgfb3 is required for heart morphogenesis and remodeling via
regulation of apoptosis and proliferation during late embryonic development. To
test this hypothesis, we generated Tgfb3 Knockout mice and we studied the effect
of Tgfb3 loss on formation and remodeling of cardiac OFT and myocardium
development via histological analysis of E13.5-P0 knockouts. Then we identified
whether Tgfb3 loss impaired cardiac cell proliferation and apoptosis in E13.5
embryos.
4.2 MATERIAL AND METHODS
4.2.1 Mice: All animal work was performed in according to a protocol approved
by the University of South Carolina Institutional Animal Care and Use
Committees (IACUCs). Tgfb3 heterozygous male and female mice (Proetzel et
al., 1995) were maintained on C57BL/6 background. Systemic ablation of Tgfb3
in mice embryos were achieved by breeding Tgfb3+/- adult male to Tgfb3+/- adult
female mice to generate Tgfb3-/- (knockout) and Tgfb3+/+ (Wild Type) littermate
embryos. Mating plugs were monitored daily and embryos were collected via a
transverse abdominal incision on euthanized pregnant mice as described in
Chapter 3. Embryos were washed 3 times in cold iced 1xPBS followed by fixation
in 4%Parformyldehyde for 24-48 hours. Genotyping was performed via
extracting DNA from tail tissue followed by PCR (see appendix for primers
sequences). Manual tissue processing was performed as follows: embryos were
washed in 1xPBS, dehydrated in 70%, 95%, and 100% alcohol, cleared in
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Xylene, immersed in Xylene/Paraffin, and imbedded in paraffin. Serial sections
were performed from the aortic arch to the whole heart at 7um thicknesses.
4.2.2 Histological analysis: Morphological examination was performed using
H&E and MF20 immunohistochemistry staining following a standard protocol as
previously described (see Chapter 2&3). Images of the serial sections were
obtained using a Nikon E400 and analyzed for the following: the presence of
aortopulmonary septation, comparing semilunar valve thickness and leaflet
number of Tgfb3 Knockouts to the littermate controls, detection of an
intraventricular septation defect, atrioventricular valve defects and myocardial
abnormalities. Cell proliferation was detected using the Anti p-HistoneH3 and
DAKO LSAB universal kit as previously described in Chapter 3. Apoptosis was
detected using TUNEL ISH following the Promega manufacture’s protocol
(FragEL™ DNA Fragmentation Detection Kit) as previously described in Chapter
2. Tgfb3 RNA scope ISH were performed following manufacture’s (Advanced Cell
Diagnostic, Inc) protocol and probe (RNAscope Probe - Mm-Tgfb3) using RNA
scope 2.5 HD BROWN Assay (cat# 322300) and RNA scope 2.5 HD Duplex Assay
kits
4.2.3 Amira 3D reconstruction of the aortic valve:
Serial sections of the entire aortic valves of three Tgfb3-/- embryos and
three littermate wild type controls (E15.5) were imaged using the Nikon E400
microscope. Tiff images were loaded into the Amira software and aligned
manually. Segmentation was performed using the Lasso tool to manually trace
the boundaries of individual leaflets on each section followed by a reconstruction
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of the 3D image (green color was assigned to the non-coronary leaflet, yellow
color was assigned to the left coronary leaflet, and red color was assigned to the
right coronary leaflet). Material Stat tool were used to measure the total volume
of each leaflet. After quantification, the surface of each 3D module was
smoothed, and the images were saved and exported as Tiff files.
4.2.4 Statistical analysis:
Statistical analysis for the comparison of two groups was performed via
GraphPad InStat software using unpaired Student t-test. One-Tailed P-values of
0.05 were considered significant. Error bars represent the standard deviations
(SD) for the groups.
4.3 RESULTS
4.3.1 Tgfb3 is expressed in both embryonic and adult mice hearts:
To detect and localize the expression of Tgfb3 in the cardiac outflow tract,
Tgfb3 RNA scope in situ hybridization was performed on formalin fixed paraffin
embedded sections of mouse embryonic and adult hearts. Tgfb3 mRNA
expression is detected around E11.5 in the cushion mesenchymal cells of
cardiac outflow tract during early heart development (Figure 4.1.A). In cardiac
chambers, Tgfb3 mRNA was differentially expressed by the myocardial cells of
the compact layer and the overlying epicardium during early heart development
and it was highly expressed in the right ventricle compared to the left ventricular
(Figure 4.1.C. D).Tgfb3 mRNA expression is also detected by the aortic valve
interstitial cells in 2 months old mice (Figure 4.1.B)
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4.3.2 Tgfb3 loss causes outflow tract alignment defects:
To test the effect of Tgfb3 loss on outflow tract formation and alignment,
histological analysis was performed on serial sections of knockout embryos
compared to littermate wild type controls. Our results show that global ablation
of Tgfb3 did not affect outflow tract formation or septation, however, it impairs
outflow tract alignment and result in double outlet right ventricle (DORV), in
which both pulmonary and aortic valves were opened into the right ventricle with
the presence of membranous ventricular septal defects between the left and
right cardiac chambers (Figure 4.6.B).
4.3.3 Tgfb3 is required for cardiac valve remodeling during heart
development
To test the effect of Tgfb3 loss on cardiac valve remolding, H&E and MF20
immunohistochemistry staining were performed on serial sections of semilunar
and atrioventricular valves. Histological examination showed that systemic
knockouts of Tgfb3 causes marked thickening of the pulmonary, aortic, mitral
and tricuspid valves compared to littermate controls (Figure 4.3 & Figure 4.6).
The aortic valve was the most affected valve in response to Tgfb3 loss where
the knockout embryos show thicker aortic valves and narrowing of the lumen
(stenosis) compared to controls (Figure 4.3). Furthermore, morphometric
measurements, via AMIRA 3D reconstruction of 3 knockouts and 3 littermate
controls, showed increased total aortic valve volume in the knockout embryos
compared to the controls (Figure 4.4 & Figure 4.5). Further measurements of
the individual leaflet’s volume per embryo showed significant increases in
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thickness of all aortic valve leaflets in the knockouts compared to the wildtype
controls (Figure 4.5).
4.3.4 Tgfb3 is required for myocardium development and chamber
septation during heart development:
We further examined the effect of Tgfb3 loss on the development of the
interventricular septum and ventricular myocardium. Three forms of ventricular
septal defects were observed in 33.33% of the Knockouts (Figure 4.7), as
follows: perimembranous VSD (5.55%), atrioventricular or inlet VSD (16.66%),
and muscular VSD (11.11%). Thinning of ventricular myocardium was observed
in 11.11% of knockouts which particularly involve the compact myocardium of
the right ventricle (Figure 4.8)
4.3.5 Tgfb3 loss impairs cell proliferation and apoptosis in the cardiac OFT
and the myocardia of the chambers:
Last, we examined the effect of Tgfb3 loss on two critical cellular events,
proliferation and apoptosis, and how they impair development of cardiac OFT
and left and right myocardium at E13.5. Our initial results show that 2 out of 3
Tgfb3 knockout mice show increased proliferation and reduced apoptosis of
cushion mesenchymal cells compared to wild type controls (Figure 4.9). In
contrast, cell proliferation of both left and right myocardia was reduced in 2 out
of 3 Tgfb3 knockout embryos with thin myocardium compared to control (Figure
4.10)
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4.4 DISCUSSION
Tgfb3

mutations

have

been

identified

in

human

patients

with

arrhythmogenic right ventricular cardiomyopathy and syndromic aortic aneurysm
(Beffagna et al., 2005; Schepers et al., 2018). However, Tgfb3 loss has not been
reported to cause major heart defects in knockout mice which die at birth due to a
cleft palate (Kaartinen et al., 1995; Proetzel et al., 1995). Here, we sought to
investigate the role of Tgfb3 in heart development using large sample sizes of 18
knockout mice between E13.5-P0. We found that approximately 45% of these mice
develop multiple cardiac developmental and/or remodeling defects. Initially we
used RNA scope in situ hybridization technology to detect the expression pattern
of Tgfb3 in embryonic and adult hearts. We found that Tgfb3 is expressed by the
OFT around E11.5 and was earlier than what was previously reported (Molin et al.,
2003). We also detected differential expression of Tgfb3 in the myocardium around
E12.5 with greater intensity in the right ventricular myocardium compared to the
left ventricle. We also reported for the first-time strong expression of Tgfb3 by the
aortic valve interstitial cells (VICs) around 2 months of age. These results suggest
that Tgfb3 plays an important role in myocardial and valve remolding and
homeostasis during embryonic and adult life. Next, we examined the effect of
Tgfb3 loss on cardiac OFT septation and alignment and we observed that only 1
out of 18 knockouts developed alignment defects (DORV), an incidental finding
that required further confirmation. In contrast, OFT remodeling defects were the
major defect identified in mice lacking Tgfb3, which develop thick stenotic
semilunar valves, particularly the aortic valve. Since the aortic valve leaflets are
derived from different cell lineages, we further measured the individual leaflet
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volume in both knockouts and littermate controls, and we found that Tgfb3 loss
similarly causes thickening of all leaflets. These results imply that Tgfb3 is primarily
required for OFT remodeling not formation which is supported by its late
expression during heart development.
Similarly, AVC cushion mesenchymal cells strongly express Tgfb3 during
heart development (Doetschman, Barnett, et al., 2012; Molin et al., 2003), and we
further examined the role of Tgfb3 on atrioventricular valve formation and
remodeling. Similarly, our initial data showed that Tgfb3 loss did not affect AV valve
formation, however, it resulted in valve remodeling defects with thickening of both
mitral and tricuspid valves.
OFT remodeling requires a balance between cell proliferation and apoptosis
which limit the number of cushion mesenchymal cells and allow subsequent
differentiation of multiple cell lineages (Poelmann, Molin, Wisse, & Gittenbergerde Groot, 2000). To further understand the role of Tgfb3 on cell proliferation of OFT
cushion mesenchymal cells, we conducted immunohistochemistry analysis using
p-Hitsone H3. Our initial data showed increase proliferation and reduced apoptosis
(in 2 out of 3 knockouts) with thickening of OFT valves compared to controls. These
data imply that Tgfb3 is expressed late in OFT morphogenesis to possibly limit
OFT proliferative capacity, enhance apoptosis, and promote semilunar valve
maturation during heart development.
The ventricular myocardium originates from two different cell lineages in
which the left ventricular myocardium arises mainly from the first heart field
derived-primary heart tube and the right ventricular myocardium arise mainly from
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the second heart field cell lineages (refer to Chapter 1 for more details)(Evans et
al., 2010; Lin et al., 2012). Proliferation of myocardial cell progenitors are critical
to increasing cardiac mass and contractility during heart development. Spatial and
temporal differences in the proliferation rates were observed during chamber
development in which the compact myocardium exhibits more proliferative
capacity than the trabecular myocardia while the proliferation lasts longer on the
right ventricular myocardium than the myocardium of the left chamber (Evans et
al., 2010; A. F. Moorman & Christoffels, 2003; van den Berg et al., 2009). Although
most studies have focused on understanding the molecular regulation of
myocardial cell specification, little is known about the signaling that regulates
proliferation of myocardial cells during development and their differentiation into
mature ventricular cardiomyocytes. We further examined the role of Tgfb3 on
myocardial development, thickness, and compaction and we found that Tgfb3
knockouts mice develop an immature thin non-compact myocardium with long
trabeculae, which was more prominent on the right side. We further checked the
number

of

proliferative

myocardial

cells

using

p-Histone

H3

immunohistochemistry, and we found reduced overall proliferation in both
chambers. However, thinning of the myocardium was more obvious on the right
ventricle than the left side which might be attributed to the fact that Tgfb3 is
expressed late during myocardial development which could have more detrimental
effect on proliferation capacity of the later second heart field derived right
ventricular myocardium, in which more intense expression of Tgfb3 is detected.
Further studies are required to determine whether myocardial cells in Tgfb3
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knockouts undergo early or more robust apoptosis, one of the main mechanisms
underlying the pathogenesis of ARVD. Furthermore, the data trends towards
increased proliferation of OFT cushion mesenchymal cells versus decreases in
proliferation of the ventricular myocardium in response to Tgfb3 loss and the
underlying regulatory mechanisms require further study.
Although our study using systemic knockout mice have shown a
comprehensive description of the effect of global TGFβ3 loss on heart
development, future work using Tgfb3flox/flox mice (Doetschman, Georgieva, et al.,
2012) is required to further understand the cell-type specific role of this ligand and
the transcriptional regulatory mechanisms underlying the pathogenesis of OFT
and myocardial developmental defects. In addition, and since our results show that
Tgfb3 plays a major role in the remodeling stage of heart development, Tamoxifen
induced Cre recombinase mice could be employed to conditionally delete Tgfb3 in
various cardiac cell types to overcome the palatogenesis defect, the major cause
of death in Tgfb3-/- mice and allow for a more extended study into adult life.
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Figure 4.1 Tgfb3 RNA expression (RNA scope ISH) in mouse embryonic
and adult hearts: (A-C) Tgfb3 RNA scope ISH (brown dots) show strong
expression of Tgfb3 in the cardiac outflow tract cushion of E11.5 mouse embryo.
(B-D) Robust Tgfb3 expression (brown dots) by the valve interstitial cells of the
aortic valve leaflet of 2-months-old mice. Pulmonary trunk (PT), outflow tract
septum (OTS), and Aorta (Ao), and Aortic valve (AoV)
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Figure 4.2 Tgfb3 RNA expression (RNA scope ISH) in mouse embryonic
cardiac chambers: (A,C) Strong Tgfb3 expression (green dots) in the right
ventricular (RV) myocardium and the overlying epicardium compared to (B,D)
the left ventricular (LV) myocardium of E12.5 embryo
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Figure 4.3 Thickening of semilunar valves in Tgfb3 Knockouts mice: (A-B)
H&E staining of E15.5 embryonic hearts show thickening of pulmonary valve
(PLV) in Tgfb3-/- compared to wild type control. (C-D) H&E staining of E15.5
embryonic hearts show thickening of aortic valve (AoV) with dilatation of the
aortic root and proximal ascending aorta in Tgfb3-/- compared to wild type
control
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Figure 4.4 Thickening of the aortic valve leaflets of Tgfb3 knockouts
compared to littermate controls: (A, C, E) Amira 3D segmentations of three
wildtype embryonic aortic valves (E15.5) show non-coronary leaflets in red,
left coronary in green, and right coronary in yellow. (B, D, F) Amira 3D
segmentations of three Tgfb3-/- embryonic aortic valves (E15.5) show
thickening of all three leaflets compared to controls. (N=6)
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Figure 4.5 Thickening of the aortic valve leaflets of Tgfb3 knockouts
(E15.5) compared to littermate controls: (A) Volumetric measurement using
the Amira material Stat tool shows significant increases in total aortic valve
leaflet volume in the Tgfb3-/- compared to wild type control (P-value=0.0161) (B)
increases in thickness of all three aortic valve leaflets in the Tgfb3-/- compared
to wild type controls (P-value=0.0162,0.024,0.0415 for LC, RC, NC
,respectively. (N=6,3 controls and 3 knockouts)
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Figure 4.6 DORV and ventricular septal defects of Tgfb3 knockouts
embryos compared to littermate controls (E13.5-E16.5): (A, C, &E) H&E
and MF20 immunohistochemistry show well developed interventricular septa
in the wild type controls. (B, D, & F) H&E and MF20 immunohistochemistry of
the Tgfb3-/- embryos show peri-membranous septal defect and DORV in B,
atrioventricular septal defects in D, and muscular septal defect with thinning of
the myocardium in D
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Figure 4.7 Thickening of atrioventricular valves in Tgfb3 Knockout mice:
(A-C) MF20 immunohistochemistry staining of E15.5 embryonic hearts show
normal mitral and tricuspid valves in wild type control mouse. (B-D) MF20
immunohistochemistry staining of E15.5 embryonic hearts show thickening of
mitral and tricuspid valves in Tgfb3-/- compared to wild type control
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Figure 4.8 Thinning of the right ventricular myocardium in E15.5 Tgfb3
knockouts compared to control: (A,C) MF20 immunohistochemistry
shows normal thickness of the right ventricular myocardium in the wild type
control. (B,D) Thinning of the compact myocardium and abnormal thin long
trabeculae of the right ventricle of the Tgfb3-/- embryo compared to control
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Figure 4.9 Increase proliferation and attenuated OFT apoptosis in
Tgfb3 knockouts compared to wild type controls of E13.5: (A, B) pHistone H3 immunohistochemistry shows increased proliferation in the OFT
of Tgfb3 KO compared to control (C, D) TUNEL ISH show reduced cell
apoptosis in the OFT of Tgfb3 KO mice compared to controls
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Figure 4.10 Reduce apoptosis in OFT of Tgfb3 knockouts compared
to wild type controls of E13.5: Morphometric analysis using image pro
plus to detect percent of apoptosis in OFT of Tgfb3 KO compared to
controls. Preliminary result shows that apoptosis was less in the OFT of 2
out of 3 knockouts compared to controls (P-value= 0.365) (N= 3
embryos/group, 3 sections/embryo)
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Figure 4.11 Reduced myocardial cell proliferation in Tgfb3 knockouts
compared to wild type controls E13.5: (A, B, C) p-Histone H3
immunohistochemistry of wild type left, IVS, and right myocardia,
respectively. (D, E, F) reduced cell proliferation in the myocardia of the
chambers of Tgfb3-/- mice compared to controls
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Figure 4.12 Increased proliferation in the OFT and attenuated
proliferation in the myocardium of Tgfb3 knockout mice compared to
wild type controls at E13.5: Morphometric analysis using image pro plus to
detect number of P-Hitson H3 positive cells per section of Tgfb3 KO
compared to control. Preliminary result shows that proliferation was more in
the OFT and less in the myocardium of 2 out of 3 Knockouts compared to
controls (P-value= 0.129 for outflow tract(OFT), P-value= 0.093 for Right
ventricle (RV), P-value= 0.2385 for interventricular septum (IVS), and Pvalue= 0.279 for left ventricle (LV) comparsins) (N= 3 embryos/group, 3
sections/embryo)
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CHAPTER 5
SUMARRAY AND CONCLUSION
Transforming growth factor Beta signaling plays a critical role in
cardiovascular development and homoeostasis, while genetic variants in its
components have been linked to cardiovascular malformations and diseases in
humans (Doetschman, Barnett, et al., 2012). The complexity of TGFβ signaling
lies in its specificity, redundancy, context dependency, and cross talk with other
major pathways (Massagué, 2012; Morikawa et al., 2016). Recent studies have
focused and addressed large aspects of the roles of TGFβ receptors and the
downstream targets in wide varieties of cardiovascular disorders, while little is
known about the role of TGFβ 1-3 ligands in cardiac outflow tract malformations
and diseases.
In the present dissertation, we described three studies aimed to
understand the specific requirements of the three TGFβ ligands in the context of
two major health issues: congenital heart defects and calcific aortic valve disease.
The main finding and the overall conclusion will be summarized for each study
accordingly:
5.1 The role of TGFβ1 in calcific aortic valve disease:
We confirmed and extended our original finding that increased TGFβ1 in
valve interstitial cells causes CAVD. We found that male mice tend to develop
severe aortic valve thickening and stenosis at 1-year of age compared to age
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matched double transgenic female mice; which develop mild CAVD without
stenosis. We also identified that male mice develop fusion of the left and right
cusps resulting in incomplete raphe formation, the most common type of aortic
valve malformation associated with human CAVD. By using transcriptomic
analysis, we found differential global gene expression and increased upregulated
expression Spp1 and Chil3 like 1 between male and females aortic valve region,
the endochondral calcification mechanism. Finally. We found that pharmacological
and genetic inhibition of TGFβ1 signaling can reduce aortic valve calcification.
Theses novel findings suggest that targeting TGFβ1 signaling could attenuate
CAVD and we speculate that it also could ameliorate the fusion of leaflets and
prevent the consequential raphe formation, one of the major potential causes of
CAVD.
In conclusion, this study provides a direct cause-effect link between
increased TGFβ1 and the development and progression of CAVD and provides a
versatile mouse model, which can be used to test different pharmacological and
alternative therapies to treat or slow disease progression in future.
5.2 The role of Tgfb2 in outflow tract malformations:
Our results confirmed and extended the original findings and provided
new information about the role of myocardial TGFβ2 in heart development. The
Tgfb2 neural crest CKOs develop thickening of aortic and pulmonary valves with
membranous septal defect. The Tgfb2 myocardial CKOs develop thick aortic
valves with membranous and muscular septa. The Tgfb2 endocardial CKOs show
failure of cardiac outflow tract septation, marked thickening of the aortic and
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pulmonary valves, and membranous septal defect. Collectively, these results
indicate that Tgfb2 expression in these cell lineages is required for OFT remodeling
while only endocardial produced Tgfb2 is critical for OFT septation. Although Tgfb2
expression in these cell lineages is essential to the development of the
membranous ventricular septum, only myocardial deletion of Tgfb2 results in
muscular septal defects. In conclusion, our results show that Tgfb2 has a distinct
cell-specific role in cardiac outflow tract morphogenesis and novel paracrine
mechanisms by which endocardial produced Tgfb2 can potentially regulate neural
crest-mediated OFT septation during heart development.
In addition, elevated Tgfb1 signaling is a signature of LDS patients with
Tgfb2 loss of function mutation (Lindsay et al., 2012), however, the contribution of
Tgfb1 to disease development remains unknown. We confirmed that endocardial
Tgfb1 overexpression causes DORV with OA in vivo and we conclude that it is
implementing in development and pathogenesis of OFT malformations.
5.3 The role of Tgfb3 in outflow tract malformations:
Our results confirmed and extended the original findings and show that
Tgfb3 knockout embryos exhibit severe semilunar valve remodeling defects with
thickening of pulmonary and aortic valves and increases in proliferation and a
reduction in apoptosis of OFT cushion mesenchymal cells. In addition, RNA scope
ISH shows differentially high expression of Tgfb3 in the right ventricular
myocardium which shows features of myocardial non-compaction and reduced cell
proliferation in Tgfb3 knockouts. In conclusion, our results indicate that Tgfb3 is
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required for both OFT remodeling and myocardial development, in part, via
regulation of cell proliferation and apoptosis.
Overall, our studies provide a comprehensive understanding of the
specific roles of the three TGFβ ligands in cardiac outflow tract malformations and
calcific aortic valve disease. The knowledge could be used to identify new
diagnostic tools, develop targeted therapies, or lineage reprograming in
regenerative medicine. Yet, to determine whether TGFβ ligands orchestrate OFT
morphogenesis and homeostasis via direct action or indirect interaction with other
pathways requires further investigation.
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